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Interest in application of flavonoids for chronic disease prevention has grown 
significantly, but the low oral bioavailability of these compounds from acute doses is 
commonly highlighted as a limitation when considering their biological significance. Still, 
the impact of broad dietary patterns such as repeated exposure on flavonoid’s 
absorption, metabolism, and eventual efficacy is critical to consider since evidence 
suggests that their bioavailability may be enhanced with repeated exposure. To fill this 
gap in knowledge, this dissertation will focus on three major areas including 
characterization of flavonoid metabolites, in addition to use of in vitro models and 
clinical work to test the effect of repeated exposure on flavonoid bioavailability.  
Though flavan-3-ols undergo Phase II metabolism in humans and rodents, 
researchers have generally not been able to utilize fully characterized standards for 
these metabolites. Thus, collaborators synthesized flavan-3-ols metabolites after which 
liquid chromatography/time-of-flight mass spectrometry (LC-TOF-MS) and nuclear 
magnetic resonance (NMR) spectroscopy were used to characterize their structure and 
match the synthesized metabolites to those found in rodent plasma. To explore changes 
xvi 
 
occurring in the upper small intestine from flavonoid repeated exposure, Caco-2 cells 
were differentiated in the presence of isolated flavan-3-ols, green tea, grape seed, or 
blackberry extracts. EGCG and EC pretreatment altered formation rate of Phase II 
metabolites, in addition, green tea and grape seed extract pretreatment both resulted in 
increased flavan-3-ol transport. In contrast, blackberry extract pretreated monolayers 
displayed decreased transport of phenolic compounds. Finally, alterations in mRNA 
expression of select transport and metabolizing genes were observed in cells pretreated 
with blackberry extract. To determine if flavonoid absorption changes with repeated 
exposure to blackberry in humans, a controlled feeding study was performed to assess 
the effect of three-week daily blackberry exposure on flavonoid pharmacokinetics. The 
results showed increased plasma AUC of peonidin glucoside after blackberry treatment 
in lean volunteers. Accumulation of total anthocyanins in urine was greater in the lean 
group after blackberry exposure. This difference may be driven by increased Phase II 
anthocyanin metabolites since there was greater accumulation of anthocyanin 
metabolites in urine in the lean group after blackberry exposure. 
Taken together, these data suggest that the small intestine may be a key 
regulator of the observed adaptive phenomena occurring in vivo. These results 
demonstrate that there is both differential transport, absorption, and metabolism of 
flavonoids, including select flavonoids and phenolic acids, after repeated exposure to 
flavonoid-rich blackberry and that this response appears to differ with BMI. These 
studies provide a basis for future work on the effect of chronic flavonoid exposure on 
their bioavailability and metabolism in a range of interventions.  
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CHAPTER 1. REVIEW OF THE LITERATURE 
 
As part of the manuscript “Altered Transport and Metabolism of Phenolic Compounds in 
Obesity and Diabetes: Implications for Functional Food Development and Assessment,” 
BW Redan1, JA Novotny2, and MG Ferruzzi1,3, in review, Advances in Nutrition. 
1Department of Nutrition Science, Purdue University, 2USDA-ARS Beltsville Human 




Plant-derived phenolic compounds are a subclass of phytochemicals characterized 
by the presence of one or more phenol moieties, and their consumption is associated 
with a reduced risk of chronic disease. While evidence has primarily been drawn from 
the epidemiological associations between foods rich in phenolics and disease-risk 
outcomes (Zamora-Ros et al., 2013a), data from in vitro studies (Tenore et al., 2013), 
animal models (Tian et al., 2013), and more crucially clinical trials have begun to 
substantiate these epidemiological associations (Hooper et al., 2012). While results are 
not fully conclusive (Jia et al., 2010), these data generally support the notion that plant-
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derived phenolic compounds likely impart benefits to humans. As a result, desire to 
expand application of phenolic compounds as a disease-preventative agent is gaining   
momentum, in part, due to the cost-effective nature of dietary prevention strategies 
relative to therapeutic approaches. This concept has been translated into formulation of 
phenolic compounds in functional foods and dietary supplements for the broader public.  
Plant-derived phenolic compounds are a subclass of phytochemicals characterized 
by the presence of one or more phenol moieties, and their consumption is associated 
with a reduced risk of chronic disease. While evidence has primarily been drawn from 
the epidemiological associations between foods rich in phenolics and disease-risk 
outcomes (Zamora-Ros et al., 2013a), data from in vitro studies (Tenore et al., 2013), 
animal models (Tian et al., 2013), and more crucially clinical trials have begun to 
substantiate these epidemiological associations (Hooper et al., 2012). While results are 
not fully conclusive (Jia et al., 2010), these data generally support the notion that plant-
derived phenolic compounds likely impart benefits to humans. As a result, desire to 
expand application of phenolic compounds as a disease-preventative agent is gaining 
momentum, in part, due to the cost-effective nature of dietary prevention strategies 
relative to therapeutic approaches. This concept has been translated into formulation of 
phenolic compounds in functional foods and dietary supplements for the broader public.  
Phenolic compounds can be broadly divided into flavonoid and non-flavonoid 
derivatives (Del Rio et al., 2013) (see Figure 1). The flavonoid class encompasses six 
major subclasses, each consisting of a three ring structure designated as A, B, and C. The 
main subclasses are flavonols, flavones, isoflavones, flavanones, anthocyanins, and 
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flavan-3-ols, which are all considered polyphenols because of their multiple phenol 
moieties. The flavan-3-ol (-)-epicatechin, which is found in high amounts in cocoa, grape 
seed, and to a lesser extent in apples and tea, has received particular attention due to is 
presence in high quantities in certain chocolates combined with chocolate’s general 
popularity. Non-flavonoid phenolics include phenolic acids, stilbenoids, and lignins. One 
of the most common dietary non-flavonoids is the phenolic acid gallic acid, present in 
grapes and other fruits. Phenolic compounds naturally occur in either free or 
glycosylated forms (Del Rio et al., 2013), which is significant since the glycoside addition 
can modulate the solubility, chemistry, and bioavailability of individual phenolic 













Figure 1. Flowchart of the main classes of phenolics with key examples of their chemical structure. 
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The phenolic contents of common foods and beverages have been systematically 
reviewed and documented in several publically available databases, including USDA’s 
Nutrient Data Laboratory Flavonoid Database and INRA’s Phenol-Explorer (Bhagwat et 
al.; Gu et al., 2004; Neveu et al., 2010; Pérez-Jiménez et al., 2010a, 2010b). The 
predominate dietary sources of phenolics in the Western diet are generally accepted to 
be fruits, vegetables, tea, wine, and cocoa products, with mean dietary intakes for 
flavonoids ranging from a low of approximately 250 mg/day for U.S. adults (Sebastian et 
al., 2015), 250-300 mg/day for Greek men and women (Zamora-Ros et al., 2015), 320 
mg/day for Korean adults (Jun et al., 2016), to a high of 1,000 mg/day for British adult 
populations (Zamora-Ros et al., 2015).  
The diverse mechanisms proposed for the biological activities of phenolic 
compounds are dependent on their structure and cellular target. Regardless of the 
structure, dietary source of the phenolic compound, or specific mechanism by which it 
may impart its biological activity, the ultimate efficacy of dietary phenolics is dependent 
on the ability of the compounds to be absorbed intact or as a biologically relevant 
metabolite, and then transported to target tissues where they can exert their biological 
activity (Ferruzzi, 2010). The bioavailability of phenolics is therefore a critical factor to 
consider when evaluating the efficacy of a food/supplement or designing products for 
at-risk populations. In addition to these factors, disease states such as obesity or 
diabetes that are common in industrialized countries (Malik et al., 2013) can impact the 
bioavailability of nutrients and potentially phytochemicals (Xiao and Högger, 2014), 
which may be related to the ability of these diseases to modulate gut function (Horowitz 
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et al., 2002; Meyer-Gerspach et al., 2014), alter regulation of xenobiotic metabolizing 
enzymes (Xiao and Högger, 2014), or perturb the gut microbial community critical to the 
metabolism of phenolics (Hartstra et al., 2015). 
This review will specifically focus on the effect of obesity and diabetes on the 
bioavailability and bioactivity of dietary phenolics. Some outstanding questions on 
absorption and metabolism of phenolic compounds include: (1) Why are phenolic 
compounds potentially more effective in improving physiological conditions in individuals 
who are lean or non-diabetic? (2) Are the absorption, metabolism, and transport of 
phenolic compounds altered in individuals with obesity or diabetes? (3) If so, what 
mechanism may be effective to target in order to increase biological activity of phenolic 
compounds in obese or diabetic individuals? 
 
1.2 Overview of the Absorption, Metabolism, and Transport of Phenolic Compounds 
Preventative or therapeutic potential of phenolic compounds is highly dependent 
on their ability to reach target tissues in a form that can exert biological function. 
Multiple steps in this process include absorption, metabolism, and transport, in both the 
upper and lower gastrointestinal tract (Neilson and Ferruzzi, 2011) (Summarized in 
Figure 2). The first key step in the absorptive process is the release of phenolics from 
the plant/food matrix into the soluble and bioaccessible fraction in the gut lumen. 
Soluble phenolic forms are then actively and passively transported from the lumen into 
the enterocyte, but then can be effluxed back out into the lumen by the action of ATP-
binding cassette (ABC) transporters. Within the enterocyte, phenolics may also be 
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metabolized prior to transport across the serosal side and into the portal vein for 
circulation to the liver, where further metabolism may occur prior to systemic 
circulation, excretion into bile/urine, or distribution to other tissues. Unabsorbed 
phenolics or those secreted back into the gut lumen are carried to the lower gut and 
made available to microbiota for catabolism into low molecular weight compounds, 
including several previously characterized phenolic metabolites (Calani et al., 2012). 
Since the broader aspects of absorption, metabolism and target tissue profiles have 
been the subject of several reviews (Clifford et al., 2013; Del Rio et al., 2010, 2013; 
Manach et al., 2005; Williamson and Manach, 2005), below are only key aspects of this 
process, focusing on upper intestinal absorption and metabolism as they rely on both 
inducible and non-inducible systems (Croom, 2012) that may be impacted by both 
health status and previous exposure to phenolics. Factors in addition to the 
metabolizing systems that are potentially affected by disease state, such as gut 








      
Figure 2. Schematic of the key molecular processes involved in the transport and metabolism of (poly)phenolic compounds (PP). 
PP-M, (poly)phenolic metabolites; MCT1, monocarboxylate transporter1; SGLT1, sodium dependent glucose transporter 1; P-gp, 
P-glycoprotein; Phase II, Phase II metabolizing enzymes; MRP3, multidrug-resistance protein 3; solid arrow, pathway of native 
phenolic compounds; dashed arrow, pathway of phenolic metabolites.    
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1.3 Absorption of Phenolic Compounds  
Absorption of phenolics in their dietary forms generally takes place in the small 
intestine, although select phenolics may be absorbed in the stomach (anthocyanins) and 
extensively in the lower intestine/colon (products of microbial catabolism). Uptake from 
the intestinal lumen by enterocytes can occur for either the glycoside or aglycone forms 
of phenolics (Del Rio et al., 2013). Glycosides of many phenolic compounds are thought 
to be translocated from the gut lumen to the enterocyte by transporters, including 
sodium-dependent glucose transporter 1 (SGLT1) and glucose transporter 2 (GLUT2). 
Since glycosidic forms are effluxed back into the intestinal lumen after uptake by the 
enterocyte (Del Rio et al., 2013), absorption efficiency is believed to be increased by first 
hydrolyzing the carbohydrate moiety attached to O-linked compounds through the 
action of enzymes produced the intestinal brush border or those synthesized by gut 
microbiota. The aglycone form of phenolics can then enter the enterocyte through 
active uptake by transporters such as monocarboxylate transporter 1 (MCT1) or to a 
certain extent by passive diffusion (Vaidyanathan and Walle, 2003). Once within the 
enterocyte, phenolics can then be metabolized (described below) or effluxed back into 
the intestinal lumen by transporters such as multidrug resistance-associated protein 1 
or 2 (MRP1/2). 
 
1.4 Metabolism of Phenolic Compounds  
Phenolics are largely transformed and transported via xenobiotic metabolizing 
systems expressed extensively in intestinal and hepatic tissues (Lampe and Chang, 2007), 
10 
 
but also in other tissues and compartments including the blood-brain barrier (Campos-
Bedolla et al., 2014; Ouzzine et al., 2014). Absorbed phenolic compounds undergo Phase 
II conjugation to produce metabolites that are less chemically reactive and either more 
hydrophilic or hydrophobic compared to the parent compound, thereby facilitating 
transport processes leading to excretion by the Phase III system through bile/feces or 
urine (see Figure 3). Since the extent to which individual phenolics are biotransformed 
may result in alteration of specific biological activity (Lambert et al., 2007; Monagas et 
al., 2010; Spencer et al., 2004), factors that ultimately affect metabolism of phenolics 
are believed to have significant impact on their potential to exert protective therapeutic 
effects at target tissues.  
The methylation of phenolics driven by catechol-O-methyltransferase (COMT) 
results in a more hydrophobic and less chemically reactive species (Croom, 2012). This 
increased hydrophobicity may then increase the association of phenolics with key 
transporters on the cell membrane, altering their transport across the enterocyte or 
other cell types (Walle, 2007), leading to the potential for accumulation of methylated 
derivatives in certain tissues such as brain (Chen et al., 2015; Ferruzzi et al., 2009; Wang 
et al., 2012). However, methylation generally decreases phenolic antioxidant capacity in 
vitro (Dueñas et al., 2010; Ishimoto et al., 2012) and thus may also affect bioactivity. For 
example, while methylation of the tea flavan-3-ol epigallocatechin-3-gallate (EGCG) 
impairs its ability to decrease tumor proliferation (Lambert et al., 2007), the flavone 
chrysin has greater anti-inflammatory ability in the human intestinal cell line Caco-2 
when methylated (During and Larondelle, 2013). In contrast, methylated epicatechin 
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glucuronide derivatives were observed to have greater ability to enhance long-term 
potentiation in hippocampal slices relative to simple glucuronides (Wang et al., 2012). 
The effect of the methylation transformation on bioactivity is a subject of significant 
debate and appears to be specific to the class of phenolic being metabolized.  
Sulfotransferases (SULT) conjugate anionic sulfate groups to phenolic moieties to 
produce a more hydrophilic species (Peters et al., 1990), resulting in either a more or 
less bioactive species depending on the cellular target (Zhang et al., 2004). For example, 
sulfate metabolites of the grape phenolic resveratrol, in contrast to the resveratrol 
aglycone and its glucuronide, are not effective in decreasing lipid content of 
differentiated adipocytes, while sulfate metabolites have been reported to be effective 
in decreasing lipid content of maturing adipocytes (Lasa et al., 2012). 
Glucuronidation conjugates glucuronic acid to phenolic compounds through the 
action of UDP-glucuronyl transferase (UGT) to yield a more hydrophilic species that can 
be efficiently eliminated (Sinnott, 1990). Glucuronidation may affect binding of 
phenolics to specific cellular targets, as in the case of resveratrol, but overall this 
biotransformation does not seem to affect resveratrol’s in vitro antioxidant potential (Lu 
et al., 2013). Additionally, in vitro models show that glucuronidation does not affect 
quercetin’s estrogenic activity (Ruotolo et al., 2014). Though this metabolite in certain 
cases does not seem to have diminished bioactivity compared to the parent compound, 
the increase in its water solubility increases its potential for excretion and thus may 




Figure 3. Summary of Phase II metabolism. Phase II metabolism of the flavan-3-ol (-)-
epicatechin (EC) can produce metabolites that differ in bioactivity due to a change in 
chemical reactivity and hydrophobicity compared to the parent compound. Conjugation 
can occur at other and additional R-OH positions than those as displayed in the figure. 
Abbreviations: UGT: UDP-glucuronyltransferase; COMT: catechol-O-methyltransferase; 
SULT: sulfotransferase. 
 
1.5 Transport of Phenolic Compounds  
After phenolics are conjugated by the Phase II metabolizing system, they can be 
transported to excretory pathways or systemic circulation leading to exposure to target 
tissues. Efflux can occur at various sites along the gut, liver, and kidney by transporters 
such as permeability glycoprotein (P-gp), also called multidrug resistant protein 1 (MDR1) 
(Walle, 2004). P-gp has a net effect of lowering apparent oral bioavailability of 
flavonoids, such as epicatechin-3-gallate (ECG), by promoting efflux from the enterocyte 
to the intestinal lumen (Vaidyanathan and Walle, 2003). However, phenolic interactions 
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with transporters may be competitive, and certain phenolic compounds that have a 
higher affinity for these MDR transporters may serve to enhance absorption of others. 
For example, gallated catechins have been shown to enhance bioavailability of other 
phenolic compounds in tea (Tagashira et al., 2012), which may be related to their ability 
to inhibit P-gp by binding to its active site (Qian et al., 2005). It is therefore important to 
consider phenolics in the context of a whole-food system containing various types of 
phenolics and other compounds, such as tea, which may lead to an overall increased 
absorption of targeted phenolics in the same system compared to isolated compounds.   
There is an important distinction to make in regard to efflux transporters, as they 
can either increase or impair delivery of phenolics to target tissues. In enterocytes, 
MRP2 localizes to the luminal side (Leslie et al., 2001), MRP3 to the serosal position, 
while MRP1 can be located on both sides (Del Rio et al., 2013; Estudante et al., 2013). 
Due to this polarization, MRP 1 or 2 can both facilitate efflux of compounds into 
excretory pathways in contrast to MRP3, which can act to enhance transport of these 
compounds to target tissues by increasing flux into the portal vein. Since the Phase II 
and efflux systems may reduce the activity of phenolic compounds, they may be a 
potential target to assess if affected in diseased conditions.  
 
1.6 Metabolic Regulation of Xenobiotic Transport and Metabolism: Potential 
Implications for Phenolics 
Since xenobiotic transport and metabolism are dependent on normal metabolic 
regulation, it can be expected that diseases such as obesity or diabetes may in fact alter 
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these systems and by extension impact bioavailability and effectiveness of phenolics. 
Several clinical trials that will be discussed have reported minimal to no improvements 
in physiological markers among obese or diabetic subjects given phenolic-rich foods, 
while there are improvements in groups without these conditions. It is therefore logical 
to assume that phenolics may not be as effective in improving health outcomes if a 
disease state such as obesity or diabetes is present. We will further review studies 
demonstrating that high therapeutic doses of phenolics are often needed to elicit 
changes in the health status of obese or diabetic individuals, further suggesting 
alterations in the absorption and metabolism of these compounds that results in their 
lowered effectiveness.  
 
1.7 Clinical Trials Comparing Efficacy of Phenolic Compounds in Healthy vs. Obese or 
Diabetic Populations  
Several studies suggest differential effects of phenolic compounds in lean versus 
obese or diabetic populations in regards to cardiovascular function. Banini et al. (Banini 
et al., 2006) found that consumption of dietary grape phenolics produced a differential 
response between diabetic and non-diabetic individuals on markers of cardiovascular 
health and glucose control. To assess this difference, diabetic and healthy individuals 
were given either 150 mL of juice, wine, or a dealcoholized wine beverages made from 
Muscadine grapes for 28 days. Non-diabetic controls in this study had a BMI range from 
about 27-30 kg/m2 (overweight), and the diabetic BMI range was from about 35-40 
kg/m2 (obese). Comparing changes in lipid profiles, grape juice consumption significantly 
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lowered triglyceride levels in only the non-diabetic participants. Diabetics consuming 
the dealcoholized wine had decreased insulin levels at the end of the study compared to 
baseline, however this reduction may simply have been from consuming less 
carbohydrate and not necessarily due to phenolic treatment. One strength of this study 
is that it tested standard wine along with dealcoholized wine, which is significant since 
alcohol can be a potential confounding factor by effecting health outcomes and/or 
bioavailability (Brien et al., 2011; Dragoni et al., 2006). While the authors did not report 
a specific phenolic composition of the juice, an analysis elsewhere suggest that 150 mL 
of the wine could contain approximately 443 mg total phenolics, including 6 mg of gallic 
acid (Otaolaurruchi et al., 2007). While this was a lower dose compared to other studies 
reviewed here, lipid profile still improved in the overweight, non-diabetic subjects, but 
the diabetic group did not show these improvements.    
Similarly, Davison et al. (Davison et al., 2008) found that higher doses of cocoa 
phenolics are needed to produce a response in cardiovascular markers and glucose 
control in overweight and obese individuals. Participants in this study had an average 
baseline BMI of 33.5 kg/m2 and were given a cocoa beverage with either low or high 
levels of flavan-3-ols (36 versus 902 mg per day). This treatment occurred over a period 
of 12 weeks, with measurement tests conducted at baseline, 6, and 12 weeks. 
Measurements at 12 weeks showed that only the high-dose group had an increase in 
flow-mediated dilatation, a marker of cardiovascular function, along with improved 
markers of insulin resistance. A strength of this study is the relatively prolonged 
treatment time period, in conjunction with the low and high doses to demonstrate the 
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point at which a physiological response takes effect. In this study, there was not a 
normal weight group to directly compare the results and the relatively high dose of 
phenolics (902 mg of flavan-3-ols) with more relevance to supplemental treatments 
rather than dietary exposure. Though this study does not point specifically to an 
underlying mechanism explaining why a much higher dose was required to elicit a 
response compared to other studies, these data suggest that a higher dose of flavan-3-
ols is needed to be effective in promoting cardiovascular health and normal insulin 
markers in overweight and obese individuals.  
Almoosawi et al. (Almoosawi et al., 2012) reported that cocoa phenolics elicit a 
differential response in cardiovascular and glucose markers in overweight and obese 
individuals versus normal weight participants. In this study, normal weight (BMI 18.5-
24.9 kg/m2) and overweight plus obese (BMI ≥ 25 kg/m2) participants were given 20 g of 
a cocoa confection containing 500 mg total phenolics (19 mg from flavan-3-ols 
epicatechin and catechin) daily for 4 weeks. The study used a crossover design, and the 
control product consisted of participants receiving a sham cocoa confection with its 
phenolics removed. The overweight/obese group had reductions in both systolic and 
diastolic blood pressure in addition to blood glucose levels at the conclusion of the 
study. The normal weight group only had a reduction in systolic blood pressure, but this 
was likely due to the normal blood pressure and glucose levels among individuals in the 
lean group. This study used a well-designed control confection that matched lipid 
profiles while excluding phenolics. As cocoa butter fatty acids alone have been reported 
to improve cardiovascular markers (Mursu et al., 2004), this suggests the direct 
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difference in phenolic impacts. One reason for observing the positive results in both the 
overweight and obese group is their categorization in the study. If the two groups were 
separated in the study, statistical analysis may have shown overweight participants 
responding to the treatment but not the obese. Though some research has not been 
able to confirm a significant relationship between BMI and effective dose of polyphenols 
(Almoosawi et al., 2010), the authors still found the results unexpected since they 
conflict with some previous research suggesting lowered efficacy of polyphenol 
treatment in obese populations. Although an effect was observed in this study on 
markers of glucose control and cardiovascular health in the overweight and obese 
population, it still leaves questions, including why studies show responders and non-
responders to phenolic treatments. This question may have been better answered if the 
overweight and obese individuals were separated into their own groups, as only those 
with BMI levels in the obese range may be negatively affected.  
Combined, these studies suggest that phenolics may have differential effects in 
lean versus obese or diabetic populations in regards to cardiovascular function. 
However, it is not clear as to the underlying reasons for this difference. It is logical that 
differences in absorption and metabolism of phenolics between healthy and obese or 
diabetic individuals would be responsible in part for these observations. With lower 
absorption, higher doses may be required to achieve appropriate circulating and tissue 
concentrations to elicit a physiological response. While the studies described did not 
directly measure absorption of phenolics, evidence from in vitro, animal, and other 
clinical studies provide more insight on this potential effect.  
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1.8 Pharmacokinetic Analyses in Animals Models Suggest Obesity and Diabetes Affect 
Xenobiotic Transport and Metabolism  
Several studies have suggested that obese or diabetic conditions may lead to a 
fundamental alteration in phenolic xenobiotic metabolism and transport systems critical 
for delivering the effect of this bioactive. Table 1 summarizes the pre-clinical animal 
models showing that both obesity and diabetes affect the xenobiotic metabolizing and 
transporting systems critical for delivery of phenolics (Lee et al., 2010). Many of these 
studies sought to determine differences in individual pharmacokinetic parameters of 
phenolics and other compounds in these diseased conditions relative to healthy models 
to help elucidate underlying mechanisms for the varying physiological responses to 














Table 1. Summary of pre-clinical pharmacokinetic studies.  
Study and 
Reference  































Liu, 2010 (64) 
Male Sprague-Dawley 
rats 
Baicalin, i.v. 10 Baicalin  12 18,000 − − 1,500 − 
 
STZ-induced diabetic rats 
    









0.2; 8.4 240 17; 19 
 
STZ-induced diabetic rats 




0.2; 8.8 500 29; 43 






8 Jatrorrhizine 34 290 150 2.88 8.5 4.4 
 
 STZ-induced diabetic 
rats     
2,150 1,050 1.88 63.2 30.9 
Liu, 2012 (75) Male Wistar rats Mangiferin ∞ Mangiferin 400 3,820 720 0.73 9.6 1.8 
 
STZ-induced diabetic rats 
    







12 Liquiritigenin  20 6,400 − − 320 − 
    
Metabolite 1 
 
13,100 223 3 min 655 11.2 
    
Metabolite 2 
 
12,300 410 3 min 615 20.5 
 










Table 1, con’d. Summary of pre-clinical pharmacokinetic studies. 
Study and 
Reference  
































    
Metabolite 1 
 
15,400 322 3 min 770 16.1 
    
Metabolite 2 
 
19,300 643 3 min 965 32.2 
 
Male Sprague-
Dawley rats  
Liquiritigenin, 
oral  
Liquiritigenin  50 297 26.0 7 min 5.94 0.52 
    
Metabolite 1 
 
34,833 132.8 15 min 697 2.7 
    
Metabolite 2 
 
32,000 246.7 15 min 640 4.9 
 
STZ-induced 
diabetic rats   
Liquiritigenin  
 
443 49.7 5 min 8.86 1.0 
    
Metabolite 1 
 
32,333 298 15 min 647 6.0 
    
Metabolite 2 
 
33,000 558 15 min 660 11.2 
Hasegawa, 
2010 (76) 
Male Donryu rats Morphine ∞ Morphine 15 12,200 − − 813 − 
 
STZ-induced 
diabetic rats     





The flavone glycoside baicalin, found in the Chinese herb Scutellaria baicalensis, 
was reported to be excreted at faster rates in diabetic compared to healthy rats (Liu et 
al., 2009). Though diabetic rats had significantly higher plasma AUC of the compound 
when provided a 200 mg/kg baicalin i.g. dose (48.48 vs. 100.77 μg∙hr∙mL-1; normal vs. 
diabetic), the normal group had significantly higher levels of the compound when given 
a 12 mg/kg dose by i.v. (18.02 vs. 11.20 μg∙hr∙mL-1; normal vs. diabetic). Since baicalin is 
transported across the ileum after the glucuronide moiety is cleaved, both groups of 
rats were tested for activity of β-glucuronidase, the enzyme that catalyzes the cleavage. 
There was a 1.7-fold increase in activity of this enzyme in the duodenum of the diabetic 
animals, demonstrating a mechanism for the observed apparent increased 
bioavailability via the oral dose. Still unanswered in this study is the underlying 
explanation for increased systemic clearance that drives the decreased baicalin plasma 
concentrations in the diabetic rats compared to the normal animals when given the i.v. 
dose.    
Cao et al. (Cao et al., 2012) reported that plasma clearance and/or decreased 
absorption of salicylic acid was altered in Goto-Kakizaki (GK) diabetic rats, a model for a 
non-obese diabetic phenotype, as compared to normal Wistar rats. Salicylic acid was 
administered in feed, and plasma samples were collected over the course of 15 weeks. 
Concentration of salicylic acid in GK rat plasma was consistently significantly lower 
compared to the Wistar rats over the course of the test period, which may be due to 
increased apparent clearance in GK (94.6 mL∙h-1kg-1) compared to Wistar rats (68.0 
mL∙h-1kg-1). Since this study administered the salicylic acid in their feed, it is also possible 
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that there were alterations in digestion or intestinal transport that decreased 
absorption of this compound. Still, the authors noted the clinical implications of the 
lower salicylic acid plasma values in the diabetic rats by concluding that diabetics may 
need increased dosage of compound to overcome increased excretion rates (Cao et al., 
2012).  
Similar effects have been observed in non-phenolic compounds that rely on 
similar transport and metabolizing pathways. Yu et al. (Yu et al., 2010) noted elevated 
plasma clearance of the phenolic-like alkaloid jatrorrhizine in diabetic Sprague-Dawley 
rats compared to healthy controls. In this study, a plant extract rich in jatrorrhizine was 
administered by intestinal perfusion, and plasma from the portal vein was collected. The 
results showed that the Cmax (maximum concentration) in diabetic animals was 9.5-fold 
greater and the AUC was 7.5-fold greater than the non-diabetic control. Probing P-gp 
function with Rho123 found it to be less active in the diabetic rats, and Western blot 
confirmed that there was also decreased protein levels of P-gp in all segments of the 
small intestine. The authors commented that compared to the normal group, there was 
a greater increase in the portal vein concentration of jatrorrhizine in the diabetic 
animals, but not a corresponding higher amount of compound in the peripheral plasma. 
This first appears to be a paradox since the compound must be transported to another 
compartment after going through the portal vein, but they seem to support the data 
from Liu et al. suggesting increased clearance from systemic circulation to urine in 
diabetic animals due to greater transport of jatrorrhizine across the small intestine but 
lower levels in the periphery.  
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1.9 Human Clinical Trials suggest Obesity and Diabetes affect Xenobiotic Transport 
and Metabolism 
Since bioactivity of phenolics is largely dependent upon their metabolism by key 
Phase II enzymes (Silberberg et al., 2006), it is necessary to consider the systems that 
may be altered in diseased conditions. Early research documented fundamental 
differences in the xenobiotic transport and metabolizing systems in obese or diabetic 
individuals (Gwilt et al., 1991). While many studies in this area have focused on 
pharmaceuticals, interestingly, the effect of disease states on these systems has also 
been investigated using phenolic compounds. As both phenolics and many 
pharmaceuticals target the Phase II and III metabolizing systems, research utilizing 
pharmaceuticals is also included in this discussion.  
For instance, Abernethy et al. demonstrated the potential influence of obesity on 
xenobiotic metabolizing systems (Abernethy et al., 1983). In this study, normal weight 
and obese subjects were given a 30 mg oral dose of the benzodiazepine oxazepam, 
excreted after glucuronidation, and it was found that plasma clearance of oxazepam 
increased significantly in the obese (157 mL/min) compared to the normal weight group 
(50 mL/min). Although doses for many pharmaceutical treatments reflect changes in 
dose based on weight, it is possible that obesity can fundamentally increase levels or 
activity of Phase II metabolizing enzymes (Brill et al., 2012). This elevated metabolism 
can result in an increase in the rate at which phenolic compounds are metabolized and 
excreted and may, in turn, decrease the potential for effective biological activity.  
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In addition, clinical studies show that pharmacokinetic parameters of the 
stilbenoid trans-resveratrol differ depending on health status of the population 
(summarized in Table 2). Boocock et al. (Boocock et al., 2007) administered 1,000 mg of 
trans-resveratrol to healthy, non-obese participants and observed an AUC of 544.8 
ng∙hr∙mL-1 and Cmax of 117 ng/mL, but when 1,500 mg of trans-resveratrol was 
administered to an overweight/obese (mean BMI = 31.8) population with hepatic 
steatosis, it resulted in an AUC of 705 ng∙hr∙mL-1 and a Cmax of 65.7 ng/mL (Chachay et al., 
2014). These studies can be more easily compared when normalizing these parameters 
by dose, which reveals that the healthy participants in Boocock et al. had an 
approximately 15% greater AUC/dose and a more striking 167% greater trans-
resveratrol Cmax/dose compared to the overweight/obese population in Chachay et al., 
demonstrating a potentially reduced ability to achieve a threshold for therapeutic 
concentrations. As non-alcoholic hepatic steatosis has been reported to be present in 
approximately 66% of obese (Sabir et al., 2001) and even 18% of lean populations 
(Younossi et al., 2012), early stages of this condition may be playing a role in liver 
function. Thus, proper liver function may potentially be affecting phenolic metabolism in 










Table 2. Comparison of clinical pharmacokinetic studies using resveratrol in overweight/obese and normal weight populations.  
Study and 
Reference 

































(mean BMI = 31.8)  














24 trans-resveratrol 1,000 544.8 117 0.76 0.54 0.117 
    
Glucuronide 1 
 
3,059 473.6 2.25 3.06 0.475 
    
Glucuronide 2 
 
2,589 672.6 1.75 2.59 0.673 
    
Sulfate 
 
10,053 2,102 2 10.1 2.10 
    
Resveratrol + 
metabolites  







1.10 Pre-clinical and In Vitro Data Suggest Obesity and Diabetes Affect the Phase II and 
III Metabolizing Systems  
The observed alterations in xenobiotic metabolism in obese and diabetic humans 
coincide with animal research done by Liu et al. (Liu et al., 2012) and additional studies 
which show differential expression of key Phase II metabolizing enzymes according to 
health status (see Table 3).When male Wistar diabetic rats were orally given 400 mg/kg 
of the xanthone mangiferin (a C-glycoside found in plants in the Anacardiaceae family), 
plasma AUC was significantly greater in the diabetic rat group (3,817.5 vs. 8,953.4 
ng∙hr∙mL-1; healthy vs. diabetic). Although PK parameters of metabolites were not 
determined, liver mRNA expression of select Ugt1a family enzymes increased 2.28-3.93-
fold, Ugt2b8 increased 4.39-fold, and Sult1a1 increased 1.62-fold in diabetic rats. In 
contrast, the liver mRNA expression of Comt decreased 1.72-fold, Ugt2b-family enzymes 
decreased by approximately 2-fold, and there was a 6.67-fold reduction in Sult1c1. 
Overall, these data indicate that differences in pharmacokinetic parameters in the 












Table 3. Summary of pre-clinical molecular-based studies.  
Study and Reference Model and Health Status Tissue Type 
Xenobiotic, Transport, and 
Metabolizing System 
Direction of Change 
Wang, 2002 (76) Male Wistar STZ-induced diabetic rats Liver COMT activity ↓ 
Braun, 1998 (85) Male B/Wor diabetic rats Liver 
Ugt1a1 
mRNA; protein; activity 
↑ 
Burant, 1994  (105) Male Sprague-Dawley STZ-induced diabetic rats Enterocytes 
Glut2, Glut5, Sglt1  
mRNA and protein  
↑ 
Maeng, 2007  (111) Male Sprague-Dawley STZ-induced diabetic rats Brain P-gp protein ↑ 
Zhang, 2011 (89) Male Sprague-Dawley STZ-induced diabetic rats Liver 
Abcb1a, Abcb1b  
mRNA; protein (P-gp) 
↓ / no change 
  
Intestinal mucosa 
Abcb1a, Abcb1b  




Abcb1a mRNA; Abcb1b mRNA; 
protein (P-gp) 
↑ / no change / ↑  
Liu, 2006 and 2007 
(91,92) 
Male Sprague-Dawley and  
ICR STZ-induced diabetic rats 
Brain cortex P-gp protein ↓ 
Nawa, 2010 (90) Male ddY STZ-induced diabetic mice Ileum P-gp protein ↓ 
van Waarde, 2002 (93) Male Wistar STZ-induced diabetic rats Liver 
Mdr2  






No change / ↓ 
Nikooie, 2013 (94) Male Wistar STZ-induced diabetic rats Soleus muscle 
Mct1 
mRNA and protein 
↓ 






Table 3, con’d. Summary of pre-clinical molecular-based studies.  
Study and Reference Model and Health Status Tissue Type 
Xenobiotic, Transport, and 
Metabolizing System 
Direction of Change 
Liu, 2012 (75) 
Male Wistar STZ-induced 
diabetic rats 
Duodenum and jejunum 









Liver Comt mRNA ↓ 
  
Liver 










Liver Sult1b1 mRNA ↓ 
Kang, 2010 (86) 
Male Sprague-Dawley STZ-
induced diabetic rats 
Liver UDP-glucuronic acid ↑ 
  
Intestine UDP-glucuronic acid no change 
Hasegawa, 2010 (83) 
Male Donryu STZ-induced 
diabetic rats 




Liver Ugt2b1 mRNA ↑ 
  
Liver Mrp2 mRNA; Mrp3 mRNA ↓ / ↑ 
Kim, 2004 (87) 
Male Sprague-Dawley vs. 
obese Zucker rats 
Liver 










Table 3, con’d. Summary of pre-clinical molecular-based studies. 
Study and Reference Model and Health Status Tissue Type 
Xenobiotic, Transport, and 
Metabolizing System 
Direction of Change 
Xu, 2012 (84) Male obese C57BL/6J Lep
ob/ob 
mice Liver 
Ugt1a1, Ugt1a6, Ugt1a9, Ugt2a3, 




Liver Ugt2b1 mRNA ↓  
Lucas-Teixeira, 2002 (77) Obese Zucker rats Jejunal mucosa COMT activity ↑ 
Koide, 2011 (78) Male C57BL/6J diet-induced obese rats Liver Total UGT activity ↑ 
  
Liver SULT2A1 protein and activity ↓ 
Kim, 2004 (87) Female C57BL/6 mice treated with LPS Liver  Sult2a1 mRNA and total SULT activity  ↓ 
Shimada, 1999 (81) Male Sprague-Dawley rats treated with LPS Liver Total SULT activity ↓ 
Ho, 2007 (113) Male Sprague-Dawley rats treated with LPS Liver Mdr1b mRNA ↑ 
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Further, Wang et al. reported that COMT methylation activity measured over 30 
min decreased by 28.1% in the liver of male Wistar rats with uncontrolled diabetes, but 
the enzyme's function was rescued by restoring blood glucose levels to a normal range 
(Wang et al., 2002). This suggests that the downstream effects from chronic elevated 
blood glucose may contribute to alterations in methylation activity. In contrast, COMT 
Vmax increased by 80.5% in obese Zucker rats in the jejunum compared to lean rats 
(Lucas-Teixeira et al., 2002). Thus, changes in COMT activity and expression appear to be 
dependent on tissue type and homeostatic aberrations, such as elevated blood glucose 
levels associated with diabetes.   
Protein levels of SULT enzymes, along with their activity, have also been reported 
to be affected by obesity, diabetes, and associated comorbidities. For instance, male 
C57BL/6J mice with diet-induced obesity have decreased protein levels of SULT2A1 in 
liver (Koide et al., 2011). Additionally, research on human clinical samples has shown 
similar trends (see summary in Table 4). Both SULT1C4 mRNA and protein expression 
has been reported to increase in humans with fatty liver, a common comorbidity of 
obesity (Hardwick et al., 2013), however liver SULT1A1 protein levels are significantly 
lower in individuals with either liver steatosis or diabetes (Yalcin et al., 2013). Thus, it 
appears that specific isoforms are differentially impacted through pathways mediated 
by inflammatory signaling associated with obesity and diabetes. For example, liver Sult 
isoforms 1a1, 1b1, and 1c1 mRNA expression and their respective proteins decreased in 
male rats after administering the inflammatory agent bacterial lipopolysaccharide (LPS) 
(Shimada et al., 1999). However, there was no reduction in Sult mRNA expression in rats 
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pretreated with the anti-inflammatory compound dexamethasone, which coinsides with 
results from another study in female C57BL/6J mice that showed a decrease in SULT 
activity under inflammatory conditions (Kim et al., 2004a). As such, both obesity and 
diabetes, as well as related inflammatory stress from these conditions appear to have a 
role in ultimate status of SULT enzymes and their activities.    
Data from animal and human studies provide conflicting information on the 
impact of obesity and/or diabetes on glucuronidation processes. Male diabetic Donryu 
rats had approximately twice the circulating concentration of morphine-3-glucuronide 
from 185-365 min after an initial 15 mg/kg morphine IV dose compared to normal 
controls  (Hasegawa et al., 2010). Additionally, Xu et al. (Xu et al., 2012) found that 
obese Lepob/ob compared to normal C57BL/6J mice had significantly increased 
acetaminophen glucuronidation velocity in hepatocytes (0.15 vs. 0.23 nmol∙min-1mg-
1∙protein), which correlated to an approximately 5-fold increase in hepatocyte mRNA 
expression of Ugt1a1 and Ugt3a1 isoforms in the obese mice. Comparing male diabetic 
BB/Wor to normal Wistar rats showed that UGT1A1 enzyme activity increased from 
0.231 to 1.816 nmol∙min-1∙mg-1 protein in permeabilized liver microsomes (Braun et al., 
1998). In streptozocin-induced diabetic male Sprague-Dawley rats, plasma AUC licorice-
derived flavanone metabolite liquiritigenin-7-O-glucuronide increased from 738 to 1,160 
μg∙min∙mL-1 and Cmax from 24.6 to 38.6 μg/mL compared to normal controls (Kang et al., 
2010). In contrast, obese Zucker rats have a statistically significant 33-63% decrease in 
the hepatic mRNA expression of the Ugt isoforms1a1, 1a6, and 2b1 compared to lean 
Sprague-Dawley rats (Kim et al., 2004b). In humans, the diabetic condition has been 
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reported to decrease both glucuronide enzyme activity and mRNA expression of the 
UGT2B7 isoform of the enzyme by approximately 50% (Dostalek et al., 2011). However, 
obese individuals are reported to have increased concentrations of oxazepam 
glucuronide metabolites (Abernethy et al., 1983), and mRNA expression of UGT1A9 and 
2B10 isoforms has been shown to be significantly higher in humans with non-alcoholic 
fatty liver disease (Hardwick et al., 2013). While data overall are somewhat mixed, 
evidence does support alteration in glucuronidation processes due to the obese or 
diabetic state. Since these changes in glucuronidation can affect overall metabolite 
profiles, excretion of phenolic compounds, and by extension apparent Cmax values, they 

















Table 4. Summary of human molecular-based studies. 
Study and Reference  Population and  Health Status Tissue Type 
Xenobiotic, Transport, and 
Metabolizing System 
Direction of Change 
Hardwick, 2013 (79) Non-alcoholic fatty liver disease Liver 
UGT1A9 and 2B10  
mRNA; protein; total UGT activity 
 ↑ / no change / no change 
   
SULTA1C4  
mRNA; protein; total SULT activity 
↑ / ↑ / ↓  
Yalcin, 2013 (80) Liver steatosis Liver 
SULT1A1  
mRNA; protein; activity  




mRNA; protein; activity 
no change / ↑ / ↓ 
Metz, 2008 (97) 
Male and female,  
lean (mean BMI = 22.6) vs. obese 
(mean BMI = 35.3) 
Leg skeletal 
muscle 
MCT1 protein  no change 
Dostalek, 2011 (88) Male and female diabetics  Liver 





UGT1A9, UGT1A1, and UGT2B7  
mRNA  
 ↓ 
Yalcin, 2013 (80) Diabetics Liver 
SULT1A1  
mRNA; protein; activity 




mRNA; protein; activity 
no change / no change / ↓  
Juel, 2004 (96) Male Type II Diabetics 
Leg skeletal 
muscle 
MCT1 protein ↓ 
Kim, 2004 (87) 
Hep 3B cells treated with TNF-α and IL-
1 
Hepatocytes SULT2A1 mRNA ↓  
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Disease state may also impact the Phase III metabolizing system by affecting P-gp 
function and expression levels. Comparing 8-week old male Sprague-Dawley rats to 
diabetic rats treated with insulin shows significantly greater Rho123 concentrations in 
the liver (69.4 vs. 120.9 ng/g; normal vs. diabetic), intestinal mucosa (101,135 vs. 
210,123 ng/g; normal vs. diabetic), and kidney (422.5 vs. 578.0 ng/g; normal vs. diabetic) 
of diabetic rats demonstrating impaired P-gp function (Zhang et al., 2011). In ileal tissue 
of diabetic male ddY mice, P-gp protein levels were 60% that of the control (Nawa et al., 
2010). Decreased P-gp function has also been demonstrated in the brain of diabetic 
male Sprague-Dawley rats by showing that the ratio of brain tissue concentration to 
plasma level of the P-gp substrate VCR is significantly greater in the diabetic group as 
compared to the control (0.023 vs 0.072 mL/brain; normal vs. diabetic) (Liu et al., 2006). 
This has been confirmed in male diabetic ICR mice, with brain concentrations of Rho 
significantly greater in diabetic rats (13.69 ng/g) compared to normal controls (10.24 
ng/g) (Liu et al., 2007). In contrast, van Waarde et al. (van Waarde et al., 2002) 
interestingly found that the liver of diabetic Wistar rats had a 530% increase in protein 
expression of MDR2 and a corresponding elevation in bile salt secretion compared to 
control.  
Though efflux transporters have an important role in the excretion of phenolics, 
expression of transporters that drive transport of phenolics into the enterocyte and 
other cells may also be altered in obesity and diabetes. In diabetic male Wistar rats, 
Mct1 mRNA expression in soleus muscle is significantly lower than control (Nikooie et al., 
2013), in addition to decreased expression of MCT1 protein in the plantaris muscle 
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(Enoki et al., 2003). Though this pattern has also been reported in male diabetic patients 
with decreased skeletal muscle expression of MCT1 (Juel et al., 2004), obese individuals 
did not show differences in muscle MCT1 protein levels compared to control (Metz et al., 
2008). Though MCT1 in human hepatic or intestinal tissue was not directly measured in 
these studies, these may similarly be affected in diseased conditions.   
 
1.11 Additional Potential Factors from the Obese and Diabetic Condition May Affect 
Phenolic Pharmacokinetics  
Although this review focused on critical xenobiotic metabolizing and transport 
systems altered by obesity and diabetes, there are additional factors to consider that 
may influence phenolic pharmacokinetic parameters in these conditions. One such 
example is that there is an increase in glomerular filtration rate from the diabetic 
condition (Premaratne et al., 2015), which could decrease plasma phenolic 
concentrations by increasing their elimination through urine. In addition, kidney disease 
that may result from late-stage diabetes can alter factors that influence xenobiotic 
metabolism (Nolin et al., 2008).  
Differences in the gut function between diabetic and normal rats may also 
partially explain differential absorption of pharmaceutical compounds. Ogata et al. 
(Ogata et al., 1997) compared absorption of the peptide cyclosporin A between GK and 
Wistar rats by administering the compound orally or by i.v. When 10 mg/kg cyclosporin 
A was given by i.v., the diabetic and normal group had similar plasma AUC of the 
compound (21.9 vs. 20.6 μg∙hr∙mL-1; normal vs. diabetic), but when orally administered, 
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the diabetic rats had significantly lower plasma AUC concentrations (11.3 vs. 1.8 
μg∙hr∙mL-1; normal vs. diabetic). Since this compound is absorbed in the small intestine, 
gastric emptying was determined using radiolabeled sodium chromate. While 90% of 
the marker could be recovered in the distal section of the ilium of the normal group 
after 2 h, only 60% could be recovered in the diabetic rats with 25% of the marker still 
remaining in the stomach. It is important to point out that while this study compared 
only two different breeds of rats, these results may be applicable in a broader sense to 
the absorption of phenolic compounds because gut transit time can impact PK 
parameters.  
Another possible factor to consider is that of intestinal microbiota since 
microbiota profiles can change under diabetic or obese conditions (Forslund et al., 2015; 
Ley et al., 2005). As phenolics have low first-pass bioavailability, they reach the lower 
gut where they may be catabolized into low-molecular weight compounds that are 
potentially absorbed and then enter systemic circulation where they can exert biological 
activity (Del Rio et al., 2013). Due to beneficial effects of phenolics potentially being 
mediated by gut microbiota, disease states that perturb microbiota composition may 
alter their efficacy (Tomás-Barberán et al., 2014). For example, Selma et al. (Selma et al., 
2015) found that production of bioactive catabolites of ellagic acid (urolithins) differ 
between overweight/obese and normal weight individuals, decreasing potential efficacy 
derived from these compounds.   
In the diabetic condition, there are alterations to intestinal tissues that occur due 
to elevated blood glucose levels, which may also affect phenolic transport. These 
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changes may emerge because expression of the small intestinal carbohydrate 
transporters SGLT1 and GLUT2 increase in diabetic rats, though controlling blood 
glucose with proper insulin treatment restores them to normal levels (Burant et al., 
1994). This alteration can then potentially increase uptake of certain phenolics whose 
transport is associated with glucose transporters.  
 
1.12 Potential Underlying Mechanism for Altered Xenobiotic Metabolizing and 
Transporting Systems in Obese and Diabetic Populations 
A potential underlying mechanism for the differences in xenobiotic transport and 
metabolism observed in obese and diabetic populations involves chronic, low-grade 
inflammatory response prevalent in these conditions (Donath and Shoelson, 2011; Neels 
and Olefsky, 2006). In a study mentioned previously, administering LPS to Sprague-
Dawley rats resulted in a 36.8% reduction in hepatic sulfonation activity (Shimada et al., 
1999), which aligns with another report that LPS-induced secretion of inflammatory 
cytokines and stimulation of the inflammatory processes alters drug metabolism 
(Waring et al., 2013). Similarly, elevated insulin levels from diabetes may also induce 
alterations that affect Phase II enzymes (Kim and Novak, 2007). In addition, Thibault et 
al. (Thibault et al., 2007) reported that individuals with inflammatory bowel disease 
have decreased expression of the MCT1 transporter, which was replicated in a 
mechanistic in vitro study demonstrating that treating the intestinal cell line HT-29 with 
the inflammatory cytokines IFN-γ and TNF-α dose dependably decreases mRNA 
expression and protein levels of this transporter. The authors of the study hypothesize 
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that the mechanism underlying this phenomenon may be due to an inflammatory 
response element in the promoter region of the MCT1 gene. Hence, inflammatory 
processes mediated though NF-κB signaling or another inflammatory signaling pathway 
likely play a role in expression of MCT1 and by extension may impact absorption of 
certain phenolics.    
Further, the inflammatory response mediated through NF-κB induction is known 
to modulate the expression of P-gp (Maeng et al., 2007). A review on P-gp expression in 
the intestine suggests that it is increased in diabetic humans due to elevated 
inflammatory cytokines and blood glucose (Kobori et al., 2013). In addition, the 
transporter MRP3 responds to inflammatory stimuli, and has been shown to become 
either up or downregulated depending on the animal model used in the study (Ho and 
Piquette-Miller, 2007). More research is needed in humans to provide a definitive 
answer on how disease states affect these transporters, however existing data do 
suggest that the diabetic condition likely increases efflux transporter activity that could 
then potentially increase excretion of phenolics.  
Additional evidence supports the relationship between increased inflammatory 
status and altered xenobiotic metabolizing and transporting systems. Individuals with 
Crohn’s disease, a condition of elevated inflammation in the gut, have increased 
expression of P-gp in intestinal and hepatic tissue (Fakhoury et al., 2006) and increased 
permeability of tight junctions, making the gut less effective in maintaining barrier 
ability (Al-Sadi et al., 2008). In addition, the elevation of protein kinase C in the diabetic 
state leads to an increase in the p65 subunit of the NF-κB transcription factor, which 
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then, in turn, increases P-gp levels in the liver (Kameyama et al., 2008; Maeng et al., 
2007). Also, MRP2/3 have both been found to be altered by increased inflammatory 
status (Ho and Piquette-Miller, 2007; Le Vee et al., 2009). Figure 4 synthesizes this 
information in a potential model to explain the altered absorption of phenolic 
compounds apparent in those with increased inflammatory status due to obesity and 
diabetes. 
 
Figure 4. Potential mechanism for altered xenobiotic transport and metabolizing 
systems in human (A) intestinal and (B) hepatic tissues. Increased NF-κB mediated 
inflammation resulting from the diabetic and obese condition are believed to be 
involved in the alterations. Dashed lines indicate potentially affected by increased NF-κB 




1.13 CONCLUSIONS & IMPLICATIONS 
Absorption, metabolism, and transport of phenolic compounds to target tissues 
are all essential for effective delivery of their bioactivity from food and dietary 
supplements, and these processes appear to be affected by disease states such as 
obesity or diabetes. The overall effect from these diseases is that they may create a 
situation where application of phenolic-rich foods or supplements may not be as 
effective as expected due to impairment of absorption and metabolism of phenolic 
compounds and increased excretion. Subsequently, formulations and therapies may 
have to be adjusted in order to accommodate for altered production of phenolic 
metabolites into circulation and target tissues. While some evidence does exist for the 
possible sources of the differences, it is critical to fully understand the underlying 
mechanism for the observed differences in phenolic effectiveness and/or bioavailability 
and metabolism between healthy and obese/diabetic individuals. Only then will 
strategies to enhance effectiveness of preventative ameliorative therapies utilizing 
these phenolic can be improved.  
Continued research on the fundamentals of the absorption and metabolism of 
phenolic compounds can help inform future studies utilizing phenolics in individuals 
with obesity or diabetes. One goal of future research should be to specifically compare 
the differential absorption of phenolic compounds in diseased versus healthy individuals. 
Study design will have to be carefully addressed in order to elucidate the mechanism for 
decreased absorption of phenolic compounds in those with obesity or diabetes. 
Including administration of phenolic compounds by i.v. would allow for assessment of 
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clearance from plasma and oral administration can assess absorption across the gut 
epithelium. Experiments of this nature are needed to confirm differences in phenolic 
absorption parameters between normal and diseased individuals. With evolving 
research that targets the fundamentals of phenolic absorption comparing healthy and 
diseased populations, researchers and product developers will be able to leverage these 
findings to develop products and strategies that better target obese or diabetic 

















CHAPTER 2. CHARACTERIZATION AND QUALITATIVE ANALYSIS OF PLASMA-TARGETED 
METABOLITES OF CATECHIN AND EPICATECHIN 
As part of the manuscript “Synthesis and quantitative analysis of plasma-targeted 
metabolites of catechin and epicatechin,” JW Blount1, BW Redan2, MG Ferruzzi2,3, BL 
Reuhs3, BR Cooper4, JS Harwood5, V Shulaev1, G Pasinetti6, RA Dixon1, published in J. 
Agric. Food Chem. 2015, 4;63(8):2233-40. 1Department of Biological Science, University 
of North Texas, 2Department of Nutrition Science, Purdue University, 3Department of 
Food Science, Purdue University, 4Bindley Bioscience Center, Purdue University, 5Purdue 
University Interdepartmental NMR Facility, 6Department of Psychiatry, The Mount Sinai 
School of Medicine 
As this publication was a collaboration, the present chapter focuses on the 
characterization and qualitative analysis of the metabolites since our collaborators 
performed their synthesis.   
Reprinted with permission from J. Agric. Food Chem., 2015, 63 (8), pp 2233–2240. 
Copyright 2015 American Chemical Society 
 
2.1 Introduction 
Plant-derived polyphenolic compounds possess diverse biological activities, 
including strong anti-tumor, anti-oxidant, anti-inflammatory, and anti-microbial
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activities (Dixon, 2001; Guo et al., 2009; Ishikawa et al., 1997). Previous work from our 
laboratories has shown that polyphenolic compounds from multiple sources, including a 
specific grape seed polyphenolic extract (GSPE), are capable of improving cognitive 
functions and reducing brain neuropathology in animal models of Alzheimer’s Disease 
through multiple mechanisms (Wang et al., 2008, 2012). At least a part of this effect 
may be mediated through interference with aggregation of β-amyloid peptides into 
neurotoxic, soluble high-molecular weight species (Wang et al., 2008).  
GSPE is a complex mixture of proanthocyanidins (PACs, both oligomeric and 
polymeric) and their monomeric units consisting of the flavan-3-ols (+)-catechin (C) and 
(-)-epicatechin (EC) (Sharma et al., 2011). The flavan-ol units are assembled into the  
various types of oligomers and polymers through C4→C8 or C4→C6 interflavan bond 
and the individual units in the polymer can also be substituted with gallic acid. The 
monomeric units, rather than the oligomers or polymers, are bioavailable and are the 
bioactive components in the GSPE (Wang et al., 2012). These bioactive components, in 
the form of glucuronidated and/or methylated phase II metabolites, reach the brain at a 
concentration of 300-400 nM after 10 days of repeated dosing (Wang et al., 2012). 
While knowledge of all metabolites found in plasma may be of broader significance for 
understanding the therapeutic effects of GSPE on a range of disease phenotypes, 
mechanistic studies, require knowledge of the exact structures of metabolites that 
accumulate in brain or other tissue. To initiate such studies, we implemented a semi-
synthetic approach to generate sufficient quantities of flavan-3-ol metabolites for 
unequivocal identification. We demonstrated that recombinant human 
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glucuronosyltransferases of the UGT1A and UGT2B families can efficiently glucuronidate 
epicatechin or 3’-O-methyl epicatechin in vitro, suggesting a method for the semi-
synthesis of  brain-targeted flavan-3-ol metabolites (Blount et al., 2012). Of twelve 
enzymes tested, UGT1A9 was the most efficient, and this enabled us to generate 3’-O-
methyl-epicatechin-5-O-glucuronide to 50% overall yield (Blount et al., 2012). In the 
present study, we have extended the above approach, in combination with chemical 
methylation of catechin and epicatechin with iodomethane, to generate authentic 
standards of the catechin and epicatechin metabolites found in the plasma and brains of 
rats treated with GSPE. The structures of the metabolites were rigorously identified, and 
we present a robust, validated protocol for the measurement of the levels of these 
compounds in animal fluids. 
 
2.2 Materials and Methods 
2.2.1 Solid Phase Extraction (SPE) of Catechin and Epicatechin Metabolites from 
Rodent Plasma 
Rodent plasma samples were obtained from a previous pharmacokinetic study 
using GSPE (Wang et al., 2012) that received approval from the Animal Care and Use 
Committee at Purdue University. Plasma aliquots from control animals (no GSPE) and 
treated animals (with GSPE) that was collected at sacrifice were thawed from -80°C 
storage and quickly pooled separately at Purdue University.  These control and GSPE 
plasma samples were then re-aliquoted into individual vials and re-frozen at -80 °C until 
analysis. For target assessment purposes, typical plasma was diluted fivefold with blank 
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plasma to produce low dose plasma. Blank, low, and normal plasma samples were then 
used for analytical validation at Purdue University and a parallel set of samples was sent 
to University of North Texas for cross-lab validation.  
Samples of frozen plasma were thawed at room temperature, and 300 µL of 
acidified saline (9g NaCl in 1000 mL 0.1% v/v formic acid/H2O) were added to 200 µL of 
plasma with vortex mixing. A SPE cartridge, 30 mg Oasis HLB column (Waters Co, Milford, 
MA), was activated by addition of 1 mL MeOH followed by 1 mL DI H2O, after which the 
plasma/saline mixture was loaded.  Loaded SPE column was first washed with 1 mL 1.5 
M formic acid, followed by 1 mL 95:5 v/v H2O: MeOH, and the eluate discarded. 
Metabolites were then eluted with 2 mL 0.1% v/v formic acid/MeOH. Following elution, 
ethyl gallate (10 µL of 10 µM stock solution) was added to the eluates as the internal 
standard prior to samples being dried under vacuum (<50 mm Hg) at 37°C. The residues 
were re-suspended in 160 µL 0.1% v/v formic acid/H2O + 40 µL 0.1% v/v formic 
acid/acetonitrile, sonicated for 10s, vortex mixed for 10s, then transferred to centrifuge 
tubes, which were centrifuged at 18,000g for 5 min to remove any particulates. The 
clear supernatants were carefully transferred to 300 µL HPLC vials for analysis.   
The ability of this extraction method to account for potential matrix effects were 
assessed by comparing response of individual metabolite standards in the presence or 
absence of blank plasma extracted matrix.  Briefly, standards of catechin and its major 
metabolites in GSPE rodent plasma at 50, 100, and 500 nM were resuspended either in 
pure solvent (160µL 0.1% v/v formic acid/H2O + 40 µL 0.1% v/v formic acid/acetonitrile - 
Standard) or in resolubilized blank plasma extracted by SPE (Standard + Matrix).  By 
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comparison of response between standards injected with or without plasma matrix an 
estimate of matrix effects was established by using the following equation: % matrix 
effect (% ME) = (peak area of standard with matrix – peak area of pure standard)/(peak 
area of pure standard) x 100% (Ćirić et al., 2012). 
 
2.2.2 LC/MS Analysis of C/EC Metabolites Extracted from Rodent Plasma 
2.2.2.1 LC-TOF-MS for unknown metabolite characterization 
Separation was achieved on an Agilent 1100 HPLC system using a Waters XBridge 
BEH shield RP-C18 XP 2.1 x 100 mm 2.5 µm column following a 2 µm frit filter. The 
column and autosampler were maintained at 40 °C and 10 °C, respectively. Mobile 
phase A was 0.1% formic acid/H2O and B was 0.1% formic acid/ACN. A linear gradient 
for elution was used at a constant flow rate of 0.26 mL/min. Initial conditions 5% B; 0-12 
min: 5-15% B; 12-18min: hold at 15% B; 18-24 min: 15-40% B; 24-30 min: 40-50% B; 30-
31 min: 50-5% B; 31-36 min: hold at 5% B to reset gradient. Injection volume was set to 
10 µL. 
Mass spectra of flavan-3-ol metabolites were obtained using an Agilent 6200 
time-of-flight (TOF) mass spectrometer in negative mode with a mass range of 100-1000 
m/z, acquisition rate of 1.4 spectra/s and 714.3 ms/spectra. Source parameters were as 
follows: gas temperature =  350 °C, drying gas = 9 L/min, nebulizer pressure = 35 psi, 
capillary potential = 3500 V, fragmentor voltage = 145 V, skimmer voltage = 60 V, and 
OCT 1 RF Vpp = 250 V. 
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2.2.2.2 LC-MS/MS for metabolite quantification 
Separation was achieved on an Agilent 1200 HPLC system as described in the 
previous section, except for the gradient conditions as follows: initial conditions 10% B; 
0-9 min: 10-35% B; 9-10 min: 35-65% B; 10-12 min: 65-10% B; 12-16 min: hold at 10% B 
to reset gradient.   
Analytes were quantified using tandem mass spectrometry (MS/MS) with an 
Agilent 6460 triple quadrupole with electrospray ionization (ESI) in negative mode using 
selected reaction monitoring (SRM) mass transitions. Acquisition SRMs were: 
catechin/epicatechin, 289 → 245 m/z; catechin/epicatechin glucuronide, 465 → 289 m/z; 
methyl catechin/epicatechin glucuronide, 479 → 303 m/z; ethyl gallate, 197 → 169 m/z. 
All mass transitions used a dwell time of 200 ms and fragmentor voltage of 135 V. 
Source parameters were as follows:  gas temperature = 350 °C, gas flow = 11 L/min, 
nebulizer pressure = 30 psi, sheath gas temperature = 350 °C, sheath gas flow = 11 L/min, 
capillary potential = 3500 V, and nozzle voltage = 1000 V. 
Intraday repeatability was assessed by extracting and analyzing pooled plasma n 
= 5 times. Interday reproducibility was determined across n = 5 days using aliquot 
pooled plasma. Repeatability and reproducibility were determined as relative coefficient 
of variation (% CV) as calculated by (standard deviation/mean) x 100%.  Limit of 
detection (LOD) was defined as S/N = 3 and limit of quantification (LOQ) as S/N = 5. Both 
values were obtained by producing serial dilutions of parent unmetabolized compounds 
and metabolites. Data are presented as mean ± standard deviation. Signal to noise (S/N) 
ratio was calculated using MassHunter software using the peak-to-peak method. 
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2.3 Results and Discussion 
2.3.1 Flavan-3-ol metabolites in rat plasma after feeding fractionated GSPE 
There are multiple compounds derived from the flavan-3-ols catechin (2,3-trans) 
and epicatechin (2,3-cis) found in mouse or rat plasma following the feeding of 
monomer enriched grape seed extract (Wang et al. 2012). LC-MS analysis has indicated 
that these compounds are glucuronides of (epi)catechin or methyl-(epi)-catechin. One 
of the most abundant metabolites in plasma was previously identified by micro NMR as 
3’-O-methyl-epicatechin-5-O-β-D-glucuronide (Figure 5), and we developed a semi-










Figure 5. Flavan-3-ol derivatives in rodent plasma. (A, B) Representative mass spectra of 
flavan-3-ol metabolites in rodent plasma obtained on a LC/TOF system with a recording 
range of 100-1000 m/z. The mass spectra of (A) is consistent with the mass of methyl-
C/EC glucuronide, while (B) is consistent with C/EC glucuronide. (C) Structure of 2,3-cis-
flavan-3-ols. Epicatechin: R1 = R2 = R3 = OH; 3ʹ-O-methyl-epicatechin-5-O-β-D-
glucuronide: R1 = glucuronic acid; R2 = OMe; R3 = OH. 
 
2.3.2 Methylation of catechin and epicatechin 
Our strategy for generation of standards of the other (epi)catechin metabolites 
found in rat plasma was to: 1) synthesize methyl derivatives of catechin and epicatechin; 
2) subject the (methylated) catechin and epicatechin to enzymatic glucuronidation; 3) 
compare LC-MS mobility and fragmentation pattern of the synthetic compound to those 
of the metabolites in plasma; 4) scale up the synthesis of compounds that match those 
in plasma and confirm their structures by NMR. 
Optimization of reaction conditions, as outlined in Materials and Methods, 
resulted in maximum yields of 3ʹ-O-methyl-(epi)catechin of around 20%. The 
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compounds corresponding to the 3ʹ- and 4ʹ-O-methyl isomers were purified by 
chromatography using a Biotage Isolera system. 
 
2.3.3 Glucuronidation of (methyl)catechin and epicatechin, and matching of synthetic 
compounds to metabolites in plasma 
Human recombinant glucuronosyltransferase UGT1A9, in the presence of UDP-
glucuronic acid, converts epicatechin to a number of products, the major one being the 
3ʹ-O-glucuronide (a compound not found in the plasma of rats or mice fed GSPE), with 
minor amounts of the 5-O-glucuronide (a minor metabolite in the plasma) (Blount et al. 
2011).  3ʹ-O-methyl epicatechin is efficiently converted to 3’-O-methyl-epicatechin 5-O-
glucuronide (a major plasma metabolite). The other compounds in plasma appear to be 
derivatives of catechin. We therefore investigated conditions for the optimal 
glucuronidation of methylated and non-methylated catechin by mammalian 
glucuronosyltransferases and UDP-glucuronic acid. In contrast to epicatechin, we found 
that pooled male mouse microsomes were more efficient at glucuronidation of catechin 
and its derivatives than was UGT1A9, resulting in two major products from catechin 
initially named CG14 and CG18 based on their approximate retention times by HPLC. 
CG14 and CG18 were further purified by semi-preparative HPLC. Both compounds 
possessed a molecular ion of 465, and matched peaks in the plasma of rats fed GSPE: 




In a similar manner, glucuronidation of 3’-O-methyl catechin by mouse 
microsomes in the presence of UDP-glucuronic acid led to the formation of multiple 
products of which two, of retention time 19 and 24 minutes and molecular ions of 479 
m/z (MCG19 and MCG24) matched metabolites in the rat plasma. Glucuronidation 
products of 4ʹ-O-methyl-catechin did not match any of the compounds found in plasma.  
 
2.3.4 Structural characterization of catechin and epicatechin metabolites 
We have previously reported the structural characterization of 3’-O-methyl-
epicatechin 5-O-glucuronide (Blount et al., 2012). In order to elucidate the structures of 
CG14, CG18, MCG19 and MCG24, NMR spectroscopy was performed using a Bruker 
Avance DRX 500 MHz spectrometer equipped with a cryoprobe. The metabolites were 
dissolved in CD3OD (99.96% atom D; Sigma, St. Louis, MO) and then transferred to a 5 
mm Shigemi tube (Wilmad Glass, Vineland, NJ). 2D NMR experiments using HSQC 
(heteronuclear correlation spectroscopy), HMBC (heteronuclear multiple bond 
correlation spectroscopy), and NOESY (nuclear Overhauser effect spectroscopy) were 
performed. The spectral data (chemical shifts) for the four compounds are shown in 
Table 5. The glucuronic acid moiety was assigned to the 7 position on (+)-catechin for 
CG-14 and MCG-19 based on the presence of a HMBC cross peak between the anomeric 
proton (H-1ʹʹ) and C-7. The assignment on CG-18 and MCG-24 was to the 5 position due 
to a HMBC cross peak between H-1ʹʹ and C-5 (Supplemental Figure 3). The methyl group 
was assigned to the 3ʹ position on MCG-19 and MCG-24 due to a NOESY cross peak 
between H-2ʹ and the methoxy group, consistent with the synthesis of these compounds 
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from 3ʹ-O-methyl catechin. Figure 6 summarizes the structures of the four catechin 
metabolites, and its legend provides further description of how the positions of 








Table 5. NMR spectral data (chemical shifts) for CG14, CG18, MCG19 and MCG24.  
CG-14 Chem. Shift (ppm) MCG-19 Chem. Shift (ppm) MCG-24 Chem. Shift (ppm) CG-18 Chem. Shift (ppm) 
Position 1H 13C Position 1H 13C Position 1H 13C Position 1H 13C 
2 4.59 82.55 2 4.63 82.54 2 4.62 83.04 2 4.59 82.53 
3 3.97 68.17 3 4.01 68.29 3 4.13 66.49 3 4.05 66.31 
4a 2.87 28.04 4a 2.90 30.88 4a 2.61 27.08 4a 3.00 28.35 
4b 2.53 — 4b 2.54 — 4b 2.17 — 4b 2.60 — 
6 6.25 96.94 6 6.22 96.94 6 6.34 97.49 6 6.27 96.76 
8 6.15 96.81 8 6.14 96.59 8 6 98.08 8 6.01 97.97 
2' 6.83 114.86 2' 6.97 111.46 2' 6.96 111.61 2' 6.81 114.83 
5' 6.71 120.27 OMe 3.84 55.83 OMe 3.83 56.4 5' 6.70 115.75 
6' 6.76 115.62 5' 6.79 115.42 5' 6.77 115.97 6' 6.75 115.50 
1'' 4.83 102.06 6' 6.83 121.44 6' 6.85 121.21 1'' 4.84 102.23 
2'' 3.45 74.23 1'' 4.84 102.03 1'' 4.82 102.81 2'' 3.48 74.43 
3'' 3.44 77.27 2'' 3.48 74.06 2'' 3.50 74.6 3'' 3.48 77.43 
4'' 3.53 72.98 3'' 3.43 74.42 3'' 3.49 77.94 4'' 3.55 73.12 
5'' 3.77 76.16 4'' 3.56 72.65 4" 3.55 73.71 5'' 3.81 76.57 
  
5'' 3.87 76.13 5" 3.69 76.59 







Figure 6. Structures assigned to CG14, CG18, MCG19 and MCG24. The glucuronic acid moiety was able to be assigned to the 7 
position on (+)-catechin for CG-14 and MCG-19 based on the presence of a HMBC cross peak between the anomeric proton (H-1ʹʹ) 
and C-7. The chemical shift of C-7 was determined by a HMBC cross peak between H-8 and C-7. Further support of this 
connectivity was provided by the absence of a cross peak between H-1ʹʹ and C-5 (chemical shift determined by a cross peak 
between H-4 and C-5). The assignment on CG-18 and MCG-24 was to the 5 position due to a HMBC cross peak between H-1ʹʹ and 
C-5. The methyl group was assigned to the 3ʹ position on MCG-19 and MCG-24 due to a NOESY cross peak between H-2ʹ and the 
methoxy group. HMBC: solid line; NOESY: dashed line
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Several studies have reported the presence of PA metabolites in blood plasma 
after feeding animals with PA preparations or foods rich in PAs (Baba et al., 2000, 2001; 
Feng, 2006; Piskula and Terao, 1998; Spencer et al., 2001). The metabolites were 
partially identified as sulfonated, glucuronidated and/or methylated derivatives of 
epicatechin and catechin (Abd El Mohsen et al., 2002; Baba et al., 2000; Piskula and 
Terao, 1998; Spencer, 2003), with most studies focusing on the epicatechin derivatives. 
Definitive structures, particularly with respect to the position of glucuronidation, were 
not systematically assigned for many of the biologically relevant metabolites. The 
present systematic approach to the synthesis and identification of predominant plasma-
derived metabolites of flavan-3-ols present in plasma of rodents dosed with GSPE 
provides a blueprint for the development of improved methods for the evaluation of 
bioavailability of bioactive polyphenols, as well as a source of standard target molecules 
for evaluating modes of action. 
 
2.3.5 Cross-validated analytical method for determining plasma levels of catechin and 
epicatechin metabolites 
LC-MS/MS using an Agilent 6460 Triple Quadrupole system was selected as the 
analytical method to determine the levels of catechin and epicatechin metabolites in 
samples of plasma from rats fed GSPE, due in part to the sensitive and selective nature 
of this method as well as the broad application of this method in the literature (Roura et 
al., 2008; Tsang et al., 2005; Urpi-Sarda et al., 2009). Initially, the linear dynamic range 
for each molecule (catechin, epicatechin, two catechin glucuronides, two methyl-
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catechin glucuronides and one methyl-epicatechin glucuronide) was determined for 
concentrations ranging over 4 orders of magnitude (pM-μM), with lowest 
concentrations in the 250-650 pM range (see Figure 7 for representative 
chromatograms). The linear dynamic range was observed to be excellent (Table 6) and 
provides the ability to quantify these compounds across a range of concentration typical 
in biological fluids and tissues. Metabolites were extracted from plasma by solid phase 
extraction (extraction recovery was estimated to be 96.0 ± 3.1% based on internal 
standard recovery) as described in Materials and Methods.  
Measurement of effects of matrix and plasma concentration, and intraday and 
interday variability revealed the method to be highly robust and efficient at limiting ion 
suppression or other matrix effects commonly reported in analysis of biological 
samples(Gardana et al., 2007; Li et al., 2007; Matuszewski et al., 2003), but rarely 
accounted for. As expected, there was a greater matrix effect at lower concentrations. 
The % ME when measuring catechin ranged from -7.84% at 500nM to -20.7% at 50nM. 
MCG24 ranged from -13.5% at 500nM to -23.0 at 50nM.  Finally, CG18 ranged from -
13.1% at 500nM to -15.7% at 50nM. Since metabolites appear in rodent plasma at 
approximately 300-400nM after repeated dosing of GSPE, using the SPE procedure 










Table 6. Linear dynamic ranges for the quantitation of (methyl)catechin and (methyl)epicatechin glucuronides by LC-MS/MS.  
 
 










C 5nM-50µM y = 7E+09x+ 528.31 0.9997 138.9 pmol 55.5 pmol 
EC 5nM-50µM y = 7E+09x+ 689.79 0.9997 106.4 pmol 48.4 pmol 
3’OMe-EC-5-O-glucr 250pM-2.5µM y=5E+11x– 3699.8 0.9998 2.05 fmol  1.07 fmol 
CG18 500pM-10µM y = 4E+11x+ 403.99 0.9999 10.6 fmol 3.41 fmol 
CG14 500pM-10µM y=6E+11x– 16601 0.9998 3.68 fmol 1.2 fmol 
MCG19 650pM-10µM y=2E+11x+ 12580 0.9990 5.80 fmol 2.80 fmol 
MCG24 500pM-20µM y=4E+11x– 31920 0.9994 4.70 fmol 1.03 fmol 
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The Horowitz ratio (HorRat), a well-recognized normalized performance 
parameter that provides a measure of laboratory precision, was calculated for 
individualized metabolites based on the equation described by Horwitz and Albert 
(Horwitz and Albert, 2006). HorRat values ranging from 0.13 to 1.29 indicated the high 
reproducibility of this method. While lower values of the HorRat (0.13-0.21) do fall 
outside of the generally accepted range, it is important to note that these were for 
minor metabolites (C-7-O-glucuronide, 3’-O-Me-C-7-O-glucuronide). Comparatively, 
values for major metabolites identified in this method, (C-5-O-glucoronide and 3’-O-Me-
5-O-glucornide) were 1.29 and 0.51, respectively. Overall these data are consistent with 
that of a highly reproducible analytical method.  
Calculated LOD (defined as 3:1 signal:noise) ranged from 1.03-3.41 fmoles on 
column for metabolites of catechin and epicatechin compared to 55.5 and 48.4 pmoles 
on column for parent compounds catechin and epicatechin, respectively. This suggests 
the potential for more efficient ionization of metabolites relative to parent compounds. 
These values translated to LOQs of 2.1-10.6 fmol on column or ~11-53 fmol per mL of 
plasma for metabolites.  
Finally, the analyses were repeated at a second site, using the identical column 
and separation parameters, but a different mass spectrometer (see Materials and 
Methods). The C and EC metabolites in the plasma were resolved by HPLC with very 
similar profiles to those recorded previously. Calibration with authentic standards 
resulted in absolute values and standard deviations that closely matched the results 
from the first site analyses, with the exception of MCG24 (3’-O-Me-C-5-O-glucoroide), 
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which was determined based on calibration with the corresponding 7-O-gluconide. It 
was observed that the C and EC metabolites were unstable in thawed plasma samples, 
as recently reported elsewhere (Zhang et al., 2013), such that reproducible results were 
only obtained if the samples were injected onto the HPLC within a few hours. Samples 
left at room temperature were almost totally degraded after 3 days. 
 
Figure 7. Chromatographic separation of and identification of C/EC metabolites for each 
mass transition. Peak identification: (a) CG14, 7-glucr; (b) CG18, 5-glucr; (c) MCG19, 7-
glucr; (d) MCG24, 5-glucr; (e) 3’OMe-EC-5-glucr. 
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2.3.6 Advantages and Disadvantages of the Present Approach  
Alternative approaches for identifying metabolites of flavan-3-ols in biological 
fluids have wither generated standard compounds by chemical synthesis (González-
Manzano et al., 2009) or attempted to identify the compounds directly from the fluids 
(Abd El Mohsen et al., 2002; Natsume et al., 2003; Piskula and Terao, 1998; Spencer, 
2003); most of these previous approaches have only unequivocally identified a subset of 
the metabolites present. A recent study has reported the chemical synthesis and full 
characterization of a complete range of EC glucuronides and sulfates (Zhang et al., 2013). 
Such compounds will be of great value for future studies on bioavailability, although 
their chemical synthesis is complex, requiring as a starting point the availability of a 
complete series of orthogonally protected EC derivatives.  
 The present study as combined a semisynthetic/biosynthetic scheme with 
matching of compounds to authentic metabolites. Although the glucuronosyl 
transferase enzymes are not completely regionspecific their mammalian origin means 
that they can generate physiologically relevant metabolites, and the matching of 
synthetic compounds to plasma metabolites prior to final purification means that only 
those metabolites that are physiologically relevant are pursued. Furthermore, an 
enzymatic strategy has advantages of the facile introduction of radiolabel, for examples, 
in the methyl (from S-adenosyl-L-methionine) or glucuronide (from UDP-glucuronic acid) 
moieties, should labeled compounds be required for mechanism of action studies or 
analytical internal standards. The limiting step from a cost perspective are the price of 
the enzymes, which cannot by recycles, and the cost of UDP-glucuronic acid. Now that 
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standards of all glucuronidated metabolites are available for subsequent identification 
of products, this problem could be circumvented by a total biological synthesis using 
recombinant enzymes express in E. coli, as we have previously shown for synthesis of 
flavonol and isoflavone glucosides (He et al., 2008). It should be notes that the present 
work does not address the sulfated derivatives that also arise from mammalian 


















CHAPTER 3. DIFFERENTIATED CACO-2 CELL MONOLAYERS EXHIBIT ADAPTATION IN 
TRANSPORT AND METABOLISM OF FLAVAN-3-OLS WITH CHRONIC EXPOSURE TO 
BOTH ISOLATED FLAVAN-3-OLS AND ENRICHED EXTRACTS 
As part of the manuscript submitted to Food & Function, BW Redan and MG Ferruzzi, 
Purdue University, Departments of Nutrition Science and Food Science 
 
3.1 Introduction   
Flavan-3-ols are key flavonoids widely distributed in the food supply and are 
naturally abundant in foods such as tea, cocoa, and grape. These compounds include 
monomeric forms such as catechin (C) and epicatechin (EC), along with complex 
proanthocyanidin (PAC) oligomers and polymers, present in grape and cocoa. 
Additionally, gallated forms including epigallocatechin gallate (EGCG) and epicatechin 
gallate (ECG) are abundant in tea. Data from epidemiological studies supports the view 
that diets rich in flavan-3-ols are associated with a decreased risk of specific chronic 
diseases including cardiovascular disease (Tresserra-Rimbau et al., 2014), diabetes 
(Zamora-Ros et al., 2013a), and certain types of cancers (Zamora-Ros et al., 2013b). 
Supporting these epidemiological associations, flavan-3-ols, and especially EC, have 
demonstrated ability to improve clinical markers related to cardiovascular function such
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as blood pressure, cholesterol, and flow-mediated dilation (Hooper et al., 2012; Sansone 
et al., 2015). However, translation of flavan-3-ols for use in disease-preventative 
strategies is limited by several factors including the notion that, excluding microbial 
metabolites, <5% of the parent compound is typically absorbed from an oral dose 
(Neilson and Ferruzzi, 2011). This is particularly true in the case of bioavailability 
assessed from an acute dose, the most predominate experimental paradigm.  
While acute bioavailability studies are most common, evidence does exist that 
longer-term exposure to flavan-3-ols that is more representative of widespread dietary 
exposure or chronic consumption of flavan-3-ol-rich foods can significantly enhance 
overall bioavailability in humans and experimental animals. Ten day administration of a 
grape seed extract product (GSE) to Sprague-Dawley rats was found to improve plasma 
response of C and EC by greater than 250% (Ferruzzi et al., 2009). Similarly, chronic GSE 
treatment in rodents increased phase II metabolites as much as 600-700% for C/EC 
glucuronides and approximately 140-240% for methyl-C/EC-glucuronides (Wang et al., 
2012). In addition, clinical research has demonstrated that 4 week chronic 
administration of 800 mg EGCG per day before a pharmacokinetic assessment results in 
EGCG plasma AUC values 60% greater than those not given EGCG (Chow et al., 2003). 
Collectively these data suggest that single acute pharmacokinetic assessments may not 
fully represent the complex response observed from longer-term dietary exposure. 
Having been observed in both pre-clinical and clinical paradigms, the implication of this 
adaption remains to be better understood and perhaps leveraged in a manner 
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consistent with understanding the bioavailability of flavan-3-ols from longer-term 
dietary patterns. 
While the exact mechanisms behind this phenomenon are not completely 
understood, what is known is that upper intestinal absorption and metabolism of 
flavonoids rely on both inducible and non-inducible metabolizing and transport systems 
(Croom, 2012) that may be impacted by previous exposure to these compounds. Since 
the gastrointestinal tract is the main barrier to delivery of flavonoids, we hypothesize 
that adaptation occurring in the upper gastrointestinal epithelium is largely controlling 
absorption of ingested compounds and may be partially responsible for the observed 
increase in flavan-3-ol absorption and metabolism with chronic exposure. Though gut 
microbiota have been reported to affect systemic delivery of phenolic compounds 
(Tomás-Barberán et al., 2014), we are focusing here on parent flavonoids and their 
Phase II metabolites since their relevance to bioactivity has been more widely studied.   
Differentiated Caco-2 monolayers are highly predictive of human absorption and 
have been employed to study absorption of a number of pharmaceuticals and 
phytochemicals because they form enterocyte-like cells (Sambuy et al., 2005). However, 
many studies involving the Caco-2 model are limited to acute studies (Hubatsch et al., 
2007) and do not consider how chronic exposure typical of dietary patterns modulates 
cellular processes associated with transport across the gut epithelium. Therefore, Caco-
2 cell monolayers were exposed throughout differentiation to isolated flavan-3-ols and 
extracts rich in flavan-3-ols to determine if adaptation in transport and metabolism of 
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these compounds could be induced in this widely-utilized model to better mimic the in 
vivo phenomenon. 
3.2 Materials and Methods 
3.2.1 Materials 
Authentic standards of (-)-epicatechin, (+)-catechin, (-)-epigallocatechin gallate, 
and (-)-epigallocatchin were obtained from Sigma (St. Louis, MO). Teavigo® (>90% EGCG) 
was used for cell culture treatments. Green tea extract was provided by Nestlé 
(Marysville, OH) and grape seed extract (MegaNatural-BP®, Polyphenolics, Madera, CA) 
was purchased from an online retailer. Solvents for liquid chromatography were of mass 
spectrometry grade and all other reagents were either cell culture or at least analytical 
grade. 
 
3.2.2 Cell culture and treatments 
Caco-2 TC7 cell line (passages 81-84) was maintained in DMEM media with 10% 
v/v FBS, 1% v/v nonessential amino acids, 1% v/v HEPES, 1% v/v penicillin/streptomycin, 
and 0.1% v/v gentamicin. Cells were incubated at 37°C under a 5% CO2/95% air 
atmosphere at constant humidity. For two compartment model experiments, cells were 
seeded at a density of 3.2 x 104 cells/mL onto 6-well plates and allowed to differentiate 
over a period up to 12 d post-confluency. For cells cultured on Transwell® inserts 
(Corning® polyester membrane, 24 mm diameter, pore size 0.4 μm), cells were seeded 
at a density of 2.12 x 105 cells/cm2 and differentiated over a period of 21-25 d post-
confluency. Cells treated with isolated compounds were cultured in growth media with 
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0 μM (control), 1 μM, or 10 μM of EC or EGCG added to the apical chamber (see Figure 8 
for outline of experimental design). Preliminary experiments indicated that cell 
monolayers could be treated with these concentrations without significantly decreasing 
cell viability (>95%) as determined by MTT assay (Biotium, Hayward, CA). Cells treated 
with extracts were cultured in growth media containing GTE rich in EGCG and ECG or 
GSE rich in C and EC monomers and polymers. Media was prepared using the same 
concentrations as pure compounds as determined by the Folin-Ciocalteu total phenolic 







Figure 8. Experimental design to simulate chronic treatment of Caco-2 cell monolayers. 
Cells were cultured in growth media with either 0 μM (control), 1 μM, or 10 μM of EGCG, 
EC, green tea, or grape seed extract added to the apical chamber. After all cell 
treatments were cultured in control media for 24 h, transport was assessed over 4 h in 
the three compartment model with a 100 μM acute dose of green tea or grape seed 
extract, while uptake and metabolism was assessed over 90 min in the two 
compartment model using a 50 μM acute dose. Abbreviations: GTE, green tea extract; 
GSE, grape seed extract; EGCG, epigallocatechin gallate; EC, epicatechin. 
 
3.2.3 Flavan-3-ol transport, uptake, and metabolism 
After a 24 h washout period in control growth media, cell monolayers were 
rinsed with 0.1% fatty-acid free albumin in PBS, followed twice with PBS only. Uptake 
and metabolism of pure compounds was assessed by an acute dose of 50 µM EC or 
EGCG in PBS (adjusted to pH = 5.5), and cells were harvested at 0 (media immediately 
removed after loading onto monolayer), 10, 30, 60, and 90 min. Transport of GTE and 
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GSE flavan-3-ols using the Transwell® system was assessed by an acute dose of 100 µM 
total phenolics in PBS (pH = 5.5). 1 mL basolateral media was collected and replaced 
with fresh PBS at 0, 15, 30, 60, 120, and 240 min. Experiments were performed in 
triplicate. After the uptake period, cells were rinsed according to the above procedure 
and then collected in ice cold PBS (pH = 5.5). The bicinchoninic acid (BCA) method using 
a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA) was used to 
determine protein levels. 
 
3.2.4 Cell extraction and transport media preparation 
Cells were lysed by sonification for 10 s, after which 1 mL of PBS and MeOH were 
added. Cells were extracted three times with 0.01% w/v BHT/ethyl acetate, organic 
layers were pooled, and then evaporated under a nitrogen stream. The extract was 
resolubilized in 100 μL of 80:20 0.4% formic acid (aq.): acetonitrile (0.1% formic acid) 
(v:v) and then centrifuged at 18,000 g for 5 min to remove particulates before injecting 
20 μL in the LC-MS-TOF system. Transport media was acidified with 1% v/v formic 
acid/acetonitrile, left on ice for 10 min to precipitate proteins, centrifuged, and injected 
as described above.   
 
3.2.5 Characterization of flavan-3-ols and metabolites 
Parent compounds and metabolites were separated using a Waters RP-C18 
column (Xbridge BEH Shield, 2.5 µm, 2.1x100 mm) and characterized using an Agilent 
1100 high-pressure liquid chromatography system in tandem with a Waters LCT Premier 
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time-of-flight mass spectrometer (LC-TOF-MS) with electrospray ionization (ESI) in 
negative mode. Flow was set to 0.25 mL/min and mobile phases were A: 0.4% formic 
acid (aq.); B: acetonitrile (0.1% formic acid). Gradient conditions were 5% B at 0 min, 35% 
B at 15 min, 70% B at 17 min, 5% B at 19 min, and 5% B at 23 min to reset the gradient. 
Extracted ion chromatograms (EICs) m/z are shown in Tables 7 and 8. Standard curves 
were produced using standards of parent compounds (C, EC, EGCG, and EGC) and were 
used to quantify intracellular/transported compounds in addition to estimating 















Table 7. Green tea (GTE) and grape seed extract (GSE) transport loading media flavan-3-






μM ± SD  
GSE  
μM ± SD 
Catechin 
(C) 289 4.83 ± 0.48 3.25 ± 0.62  
Epicatechin 
(EC) 289 21.9 ± 1.0 6.34 ± 1.23  
Epigallocatechin 
(EGC) 305 35.2 ± 1.9  Not quantified 
Epicatechin gallate 
(ECG) 441 0.94 ± 0.050 Not detected 
Epigallocatechin gallate  
(EGCG) 457 24.1 ± 1.2  Not detected 
Proanthocyanidin dimer B2 





3.2.6 Data analysis 
Values for cellular accumulation of flavan-3-ols and metabolites are expressed as 
average pmol ± SEM. Linear regression using Excel was performed to determine the 
slope for use in rate calculations (Microsoft, Redmond, WA). The apparent permeability 
coefficient (Papp) was calculated using an equation for use in Caco-2 transport studies 
(Hubatsch et al., 2007). Analysis was performed using SAS 9.3 (SAS Institute, Cary, NC), 
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3.3.1 Monomeric flavan-3-ol composition of extracts and stability to experimental 
conditions 
GTE shows a similar profile of flavan-3-ols as previously reported (Neilson et al., 
2010), with the major compounds being EGCG and EGC (Table 7). Concentrations of 
these compounds in this extract though appear to have lower amounts of gallated with 
respect to non-gallated flavan-3-ols. Average recovery of flavan-3-ols over 4 h in cell-
free transport media was 92.1%. Table 7 shows the concentrations of C, EC, and PAC B2 
in the transport media, which was within the range of that previously reported (Villani 
et al., 2015). Average recovery of these flavan-3-ols over 4 h in cell-free transport media 
was 79.5%. 
 
3.3.2 Differential cellular uptake and metabolism of flavan-3-ols 
In addition to unmetabolized EGCG and EC, methylated and sulfonated 
metabolites of these compounds were detected in Caco-2 cells. Figure 9 shows 
representative chromatograms of intracellular EGCG, EC, and their metabolites, which is 
similar to previous reports of Caco-2 cell metabolism of flavan-3-ols (Sanchez-Bridge et 
al., 2015; Zhang et al., 2004). After 30 min, 1 μM EGCG pretreated monolayers showed 
significantly (P < 0.05) greater accumulation of EGCG compared to control (80.8 vs. 189 
72 
 
pmol/mg protein; control vs. 1 μM pretreatment), but no other differences in 
accumulation were observed (Figure 10). While there was no alteration in the rate of 
EGCG uptake or methylated EGCG appearance with treatments, 10 μM EGCG 
pretreatment decreased appearance rate of both sulfated (0.27 vs. 0.063 pmol∙min-1∙mg 
protein-1; control vs. 10 μM pretreatment; P < 0.01) and methyl sulfate derivatives (0.23 
vs. 0.070 pmol∙min-1∙mg protein-1; control vs. 10 μM pretreatment; P < 0.05) compared 
to control (Table 8). 
After 60 min, both 1 and 10 μM EC pretreatments resulted in significantly (P < 
0.05) greater EC accumulation compared to control (221 pmol/mg protein, control; 376 
pmol/mg protein, 1 μM pretreatment; 352 pmol/mg protein, 10 μM pretreatment), with 
the 1 μM pretreatment remaining significantly greater after 90 min (273 vs. 569 
pmol/mg protein; control vs. 1 μM treatment). Similarly, both treatments displayed 
significantly (P < 0.05) greater levels of methylated EC derivatives after 60 min (38.5 
pmol/mg protein, control; 64.4 pmol/mg protein, 1 μM pretreatment; 71.2, 10 μM 
pretreatment; pmol/mg protein), with the 10 μM pretreatment showing approximately 
twice the concentration of methylated EC at 90 min (46.5 vs. 101 pmol/mg protein; 
control vs. 10 μM pretreatment; P < 0.05). Rate of cell accumulation of EC and its 
metabolites over 90 min showed that while 10 μM pretreated monolayers had a 
significantly increased rate of EC methylation (0.43 vs. 1.03 pmol∙min-1∙mg protein-1; 
control vs. 10 μM pretreatment; P < 0.01) there was decreased appearance of sulfated 
derivatives (0.90 vs. 0.53 pmol∙min-1∙mg protein-1; control vs. 10 μM pretreatment; P < 
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0.05). No significant differences were observed in the rate of appearance of methylated-
EC sulfate metabolites with pretreatment.   
 
Figure 9. Representative chromatograms of intracellular EGCG, EC, and their respective 
metabolites. Tentative identification of peaks: a, EGCG; b, Me-EGCG; c, EGCG-S; d, Me-
EGCG-S; e, dimethyl-EGCG; f, EC; g, 3’methyl-O-EC; h, 4’-O-methyl-EC; i, EC-S; j, Me-EC-S.   
 
3.3.3 Differential alteration in transport of flavan-3-ol-rich extracts across Caco-2 
monolayers 
Since major flavan-3-ol Phase II metabolites of the parent compounds were not 
observed to a great extent in the three compartment model, we focused on tracking the 
parent compounds for flux through the cell monolayers. Figure 11 shows that after 4 h, 
10 μM GTE pretreatment resulted in 38% greater cumulative transport of EC compared 
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to control (12.1 vs. 16.7 nmol; control vs. 10 μM pretreatment; P < 0.05). GTE 
pretreatment resulted in significant (P < 0.05) differences in transport of gallated flavan-
3-ols at 60 min, with approximately 60% greater cumulative transport of EGCG (0.56 vs. 
0.89 nmol; control vs. 1 μM pretreatment) and a 44-61% increase in ECG transport (0.16 
nmol, control; 0.26 nmol, 1 uM pretreatment, 0.23 nmol, 10 uM pretreatment). For 
monolayers pretreated with 10 μM grape seed extract, there was significantly (P < 0.05) 
greater cumulative transport of C (2.0 vs. 3.1 nmol; control vs. 10 uM pretreatment), EC 
(5.4 vs. 6.3 nmol; control vs. 10 uM pretreatment), and PAC B2 (1.0 vs. 1.5 nmol; control 
vs. 10 uM pretreatment) after 4 h (see Figure 11). No significant differences were 
observed in cellular accumulation of flavan-3-ols with tea or grape seed extract 









Figure 10. Effect of pretreatment on Caco-2 uptake and metabolism of EGCG and EC 
over 90 min was assessed using monolayers differentiated in a 6-well two compartment 
model. Monolayers were exposed to either 0 μM (control), 1 μM or 10 μM EGCG or EC 
pretreatment (PT) in growth media following the paradigm and conditions described in 
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(Figure 10 caption, con’d.) Parent compounds, along with the methylated and 
sulfonated metabolites were identified by LC-TOF-MS. *P < 0.05 compared to control. 
 
Figure 11. Chronic pretreatment with green tea extract differentially alters  
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(Figure 11 caption, cont’d.) apical to basolateral transport of flavan-3-ols across 
differentiated Caco-2 cell monolayers. Confluent Caco-2 monolayers were cultured on 
Transwell® inserts in pretreatment (PT) media containing either 0 μM (control), 1 μM, or 
10 µM total green tea or grape seed phenolics (see Table 1 for composition of transport 
media) during the differentiation process. All cell monolayers were incubated with 
control media 24 h before transport was assessed using a 100 µM total phenolics acute 
dose of total green tea or grape seed extract over 4 h. Statistical pairwise comparison 
was performed comparing 0 µM (control) to treatments. *P < 0.05 compared to control. 
Abbreviations: PT, pretreatment; C, catechin; EC, epicatechin; ECG, epicatechin gallate; 





Figure 12. Pretreatment Increases Transepithelial Electrical Resistance (TEER) values. 
Caco-2 cells grown on Transwell® inserts (n = 3) were pretreated with either 0 (control), 
1, or 10 µM total phenolics of green tea extract (GTE) or grape seed extract (GSE) 
indicating an increase in formation of cellular tight junctions. Differing letters indicate 






Table 9 displays the apparent permeability coefficient (Papp) calculated from the 
transcellular flux of each parent flavan-3-ol compound from green tea and grape seed 
extracts. After 2 h, 1 μM GTE pretreated monolayers showed greater (P < 0.01) Papp of C 
(7.05 x 107 cm/s vs. 4.93 x 107 cm/s; control vs 1 μM pretreatment) and EC (5.23 x 107 
cm/s vs. 7.64 x 107 cm/s; control vs 1 μM pretreatment) compared to control, though 
there was a tread in significance for increased EC Papp with 10 μM pretreatment (P = 
0.0599). Similarly, significant (P < 0.05) differences in C transport were observed over 2 
h in monolayers receiving 10 μM GSE pretreatment (6.54 x 107 cm/s vs. 7.46 x 107 cm/s; 
control vs 1 μM pretreatment). Additionally, there was a trend (P = 0.0515) for 
increased PAC B2 Papp over 4 h with 10 μM GSE pretreatment. Interestingly, 10 μM 
pretreatment with both green tea and grape seed extracts significantly (P < 0.05) 
increased transepithelial electrical resistance (TEER) of differentiated monolayers 












Table 8. Rate (pmol/min) of differentiated Caco-2 cell accumulation of EGCG/EC and 










) over 90 min 
EGCG 457 
0 µM 3.67 ± 0.334 
1 µM 3.67 ± 0.337 
10 µM 2.67 ± 0.334 
Methyl-EGCG 471 
0 µM  3.33 ± 0.334 
1 µM 3.67 ± 0.334 
10 µM 3.00 ± 0.578 
EGCG Sulfate 537 
0 µM 0.267 ± 0.0334 
1 µM 0.367 ± 0.0667 




0 µM 0.233 ± 0.0334 
1 µM 0.600 ± 0.0578** 
10 µM 0.0700 ± 0.0173* 
EC 289 
0 µM 3.00 ± 0.578  
1 µM 6.00 ± 1.01
#
 
10 µM 5.00 ± 4.33 
Methyl-EC 303 
0 µM 0.433 ± 0.0667 
1 µM 0.833 ± 0.120* 
10 µM 1.03 ± 0.0334** 
EC Sulfate 369 
0 µM 0.900 ± 0.0578 
1 µM 2.00 ± 0.578 
10 µM 0.533 ± 0.0667* 
  Methyl-EC 
Sulfate 
383 
0 µM  0.0533 ± 0.0241 
1 µM 0.153 ± 0.0467 
10 µM 0.0120 ± 0.00405 
aValues are presented as average (n = 3) ± SEM. Statistical pairwise comparison is between pretreatments 
and 0 µM. *P<0.05; **P<0.01; #P=0.0602. 
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Table 9. Apparent permeability coefficients (Papp) of green tea (GTE) or grape seed (GSE) 
extract flavan-3-ols across differentiated Caco-2 cell monolayers.a 
Compound Pretreatment P
app
 ±  SEM (x 10
7
 cm/s) over 2 h P
app
 ±  SEM (x 10
7
 cm/s) over 4 h 
C 
(GTE) 
0 µM 4.93 ± 0.336 6.32 ± 0.274 
1 µM 7.05 ± 0.0966** 6.48 ± 1.30 
10 µM 8.45 ± 3.24 5.86 ± 0.382 
EC 
(GTE) 
0 µM 5.23 ± 0.389  6.57 ± 0.652  
1 µM 7.15 ± 0.117** 6.28 ± 0.798 
10 µM 7.64 ± 0.834
#
 7.18 ± 0.105 
EGCG 
(GTE) 
0 µM 2.64 ± 0.322 2.47 ± 0.216 
1 µM 2.68 ± 0.370 2.51 ± 0.314 
10 µM 2.65 ± 0.157 2.72 ± 0.0715 
ECG 
(GTE) 
0 µM  9.18 ± 0.896 9.44 ± 0.801 
1 µM 10.8 ± 1.28 9.37 ± 1.03 
10 µM 9.87 ± 0.666 9.76 ± 0.211 
EGC 
(GTE) 
0 µM  4.80 ± 0.809 4.61 ± 0.243 
1 µM 5.04 ± 0.438 4.48 ± 0.117 





0 µM 6.54 ± 0.441 5.79 ± 0.285 
1 µM 4.75 ± 0.0912 5.47 ± 0.0237 
10 µM 7.46 ± 1.39* 8.79 ± 1.04 
EC 
(GSE) 
0 µM 6.94 ± 0.980  7.90 ± 0.101 
1 µM  6.01 ± 0.222 6.89 ± 0.549 
10 µM 10.3 ± 3.05 9.47 ± 0.651 
PAC B2 
(GSE) 
0 µM 6.02 ± 0.703 4.23 ± 0.0297 
1 µM 6.45 ± 1.79 3.84 ± 1.96 
10 µM  7.31 ± 0.896 6.07 ± 0.453
†
 
aValues are presented as average (n = 3) ± SEM. Statistical pairwise comparison is 






The Caco-2 human intestinal cell model is commonly used to investigate factors 
impacting absorption and to a certain extent metabolism of dietary flavonoids. However, 
typical experimental paradigms used in cell-based studies rely on acute exposures that 
may not mimic chronic dietary exposure to flavonoids. The extent to which the Caco-2 
model can exhibit adaptive responses similar to those observed in humans and 
experimental animals is critical to establish in order to enhance the predictive nature of 
this important model. Our data suggest Caco-2 cell human intestinal cell monolayers 
may, in fact, adapt differentially to transport of gallated versus non-gallated flavan-3-ols 
with exposure to these phenolics during differentiation. While non-gallated flavan-3-ols 
(C and EC) generally exhibited greater levels of cumulative transport at later time points 
with pretreatment (2-4 h; see Figure 10), gallated flavan-3-ols (EGCG and ECG) showed 
differences in transport and accumulation at 30 and 60 min time points (See Figures 10 
and 11). Since gallated flavan-3-ols are less bioavailable as compared to non-
gallated,(Zhang et al., 2004) these points where alterations in transport and 
accumulation occurred may be a reflection of different absorption efficiencies or 
perhaps transport mechanisms being affected by chronic exposure to gallated and non-
gallated flavan-3-ols. Similarly, Caco-2 cell monolayers pretreated with grape 
anthocyanins for 96 h exhibit approximately 50% greater transport of these compounds 
compared to untreated cells (Faria et al., 2009), indicating that different classes of 
flavonoids may induce an adaptive response.  
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Still, permeability coefficients of the transported flavan-3-ols (see Table 9) 
corresponds with previous values reported in literature (Zhang et al., 2004) and are 
indicative of their low oral bioavailability (Papp < 2 x 10-5) (Hubatsch et al., 2007). Since 
pretreatment with both extracts significantly increased TEER values, this suggests that 
pretreatment impacted tight junction proteins and that the observed increases in 
flavan-3-ols transcellular flux are not mediated by paracellular transport. An increase in 
tight junction proteins has similarly been observed in rodents treated with grape seed 
extract (Goodrich et al., 2012), which may be linked to this treatment resulting in a 
reduction of a marker of gut neutrophil infiltration in these animals. 
Though there were no differences in intracellular methylated EGCG 
concentrations with pretreatment, there was a significantly decrease in formation rate 
of both sulfate and methyl sulfate metabolites with 10 µM pretreatment. These data 
suggest a inhibitory effect of flavan-3-ol pretreatment on these processes, as flavonoids 
have been reported to inhibit sulfotransferases (James and Ambadapadi, 2013). This is 
in contrast to a report of HepG2 hepatocytes pretreated for 24-48 h with 10 µM 
resveratrol that showed increased gene and protein expression of sulfotransferase 
enzymes (Lançon et al., 2007). This suggests that class of the phenolic used in 
treatments and length of treatment time combined with tissue type may be critical to 
consider in assessing their influences on Phase II metabolizing systems. Though we 
observed transient increases in transport with EGCG pretreatment, an animal study with 
a two-week pretreatment of 0.32% EGCG diet observed an approximately 50% 
reduction in EGCG plasma AUC (James et al., 2015). However, his study did not measure 
83 
 
metabolites of the compound and it is possible that enhanced metabolism could be 
responsible for the reduction in levels of circulating native EGCG. In contrast, a clinical 
study with a two week run-in period providing 800 mg EGCG per day resulted in ≈60% 
increase in plasma AUC (Chow et al., 2003), indicating that there may be a differential 
response to pretreatment depending on the specifics of the experimental design. 
In contrast to EGCG pretreatment decreasing metabolizing systems, there was 
significantly greater concentrations of methylated EC metabolites with pretreatment at 
60-90 min (Figure 10). Since 10 µM pretreatment did not significantly increase 
intracellular concentrations of EC but methylated EC did increase, the increase in 
methylated EC levels may not simply be due to increased intracellular levels of the 
parent compound but may in fact reflect induction of methylation systems or EC being 
preferentially trafficked to these systems for more efficient conjugation. However, this 
was not fully assessed in these experiments and remains to be investigated. In contrast, 
we observed a significantly lower appearance rate of EC sulfate metabolites with 10 µM 
pretreatment compared to control (Table 8), suggesting differential regulation of the 
individual Phase II systems with pretreatment. Taken together, changes in metabolism 
of phenolic compounds occurring in intestinal tissues with chronic exposure may shift its 
metabolism to other tissues such as the liver which then may then results in an altered 
systemic metabolite profile.  
We were not able to detect glucuronide metabolites of flavan-3-ols using our 
model, though some (Rodriguez-Mateos et al., 2014) but not others (Sanchez-Bridge et 
al., 2015) have been able to detect this metabolite. This may be related to differences in 
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analytical methods used in addition to varying cell culture conditions, treatment 
concentrations, and length of treatment times. In addition, we did not observe 
significant levels of metabolites in the three compartment model. Again, this may be 
related to our use of extracts rather than isolated compounds, which may provide 
additional substrate that saturate the metabolizing systems (Sanchez-Bridge et al., 2015). 
In comparing our results to in vivo models, we did not observe a similar magnitude of 
effects in the adaptive response in our cell model as compared to animal studies 
previously cited (Ferruzzi et al., 2009; Wang et al., 2012). This may be due, in part, to 
differences in the pretreatment concentrations used in the studies and the actual 
concentrations employed in the animal studies. Luminal concentrations in the cited 
animal studies are estimated to be in the order of ≈4.3 mM concentrations of 
monomeric (epi)catechins (Kararli, 1995), in contrast to the lower pretreatment 
concentrations used in our study (1-10 µM). Thus our experimental paradigm may be 
more indicative of modest dietary consumption of flavan-3-ols, while the animal study 
represents what may be occurring with exposure to amounts common in dietary 
supplements. Though luminal concentration of flavonoids could potentially be higher 
from typical servings of foods (Scalbert and Williamson, 2000), relatively low doses were 
chosen here were based on preliminary screening of cytotoxicity and to mimic more 
modest concentrations of flavan-3-ols achieved by typical consumption in the U.S. (Kim 
et al., 2014). Another point to consider is that though we did not quantify 
proanthocyanidins in the grape seed extract, they appear to be an important 
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component in the observed adaptive response in animal models that occurs with 
chronic exposure to C/EC monomers and polymers. 
Since differentiation of intestinal cells is influenced by its matrix (Reya and 
Clevers, 2005), it is plausible that altering that environment will affect the 
differentiation process. In support of this, Caco-2 cells chronically treated with flavan-3-
ol-rich grape seed and other grape products over ≈30 d exhibit differences in expression 
of classic markers of differentiation such as sucrase-isomaltase and aminopeptidase N 
(Laurent et al., 2004, 2005). Though the present experiments did not measure markers 
of differentiation, we did observe increases in TEER values with treatment, which may 
indicate altered differentiation. Also, other tissue types appear to respond to 
pretreatment as primary hepatocytes have altered gene expression of organic anion 
transporting polypeptides (OATPs) with long-term exposure to select anthocyanins (Riha 
et al., 2015). As these markers were not followed specifically in this study, future work 
will be required to identify specific proteins that may be altered with pretreatment such 
as efflux transporters, which have been reported to be affected by the phenolic acid 
caffeic acid (Hong et al., 2015).  
A limitation of this model is that it does not consider other tissues involved in 
absorption and transport of flavonoids, such as the liver and kidney. In addition, it only 
focuses on adaptation occurring in the upper gastrointestinal tract, which does not 
incorporate changes in gut microbiota in the lower bowel that may occur with a 
flavonoid-rich diet. Ultimately, it is important to consider absorption and metabolism of 
these compounds in the context of a diet, where there can be multiple interactions 
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between food components and individual flavonoids that can alter metabolism of other 
compounds (Zhang et al., 2004; Zhu et al., 2008). Still, these results suggest that 
intestinal adaptation to chronic exposure to both isolated flavan-3-ols and extracts rich 
in flavan-3-ols can alters flavan-3-ol transport and potentially intestinal barrier function. 
 
3.5 Conclusion 
Our data suggest pretreatment with isolated flavan-3-ols and extracts rich in these 
compounds are both able to elicit an adaptive response in the Caco-2 cell model that is 
directionally reflective of in vivo adaptations previously documented. Since this model is 
widely used to predict the bioavailability of phytochemicals, the experimental paradigm 
of chronic exposure could possibly allow for more accurate assessment of the 
absorption and metabolism of these compounds from exposure due to broad dietary 
patterns. In addition to the increased transport of green tea and grape seed flavan-3-ols 
observed with pretreatment, differences in EGCG and EC metabolite profile with 
pretreatment were observed. These data compare to previous pre-clinical and clinical 
studies demonstrating adaptation with chronic exposure to these compounds. Though 
not directly assessed in these experiments, increased flux of flavan-3-ols observed after 
pretreatment suggests induction of more efficient cellular trafficking of the compounds. 
More complex models incorporating aspects of Phase II metabolism other than 
intestinal metabolism may assist in elucidating alterations occurring at other tissue sites. 
In addition, future studies can further explore this question by determining molecular 
mechanisms involved in this adaptive response. Taken together, these results 
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demonstrate that the Caco-2 cell model may be used model alterations in intestinal 






















CHAPTER 4. ADAPTATION IN CACO-2 HUMAN INTESTINAL CELL DIFFERENTIATION 
AND PHENOLIC TRANSPORT WITH CHRONIC EXPOSURE TO PHENOLIC-RICH 
BLACKBERRY (RUBUS SP.) EXTRACT  
As part of the manuscript in review in Molecular Nutrition & Food Research, BW Redan1, 
GP Albaugh2, CS Charron2, JA Novotny2, and MG Ferruzzi,1,3 
1Department of Nutrition Science, Purdue University, 2USDA-ARS Beltsville Human 
Nutrition Research Center, 3Department of Food Science, Purdue University 
 
4.1 Introduction 
Berries are a rich dietary source of bioactive phenolic compounds including 
anthocyanins, phenolic acids, flavonols, and flavan-3-ols. Though consensus has not 
been reached (Jacques et al., 2015), data from epidemiological studies conducted in 
various populations support the notion that diets high in fruits, including berries, are 
associated with a decreased risk of chronic disease and overall mortality (Du et al., 2016; 
Hjartåker et al., 2015). In addition, data from clinical studies have shown that 
consumption of dietary sources of anthocyanins and other flavonoids from berries can 
improve risk factors for cardiovascular disease such as blood pressure and lipid profiles 
(Kianbakht et al., 2014; Novotny et al., 2015). As such, blackberry (Rubus sp.) was 
selected for these studies since it is rich in the anthocyanin cyanidin-3-O-glucoside, the 
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aglycone of which is the most common in the food supply and most highly consumed 
anthocyanin form (Wu et al., 2006). Blackberries contain primarily cyanidin-3-O-
glucoside and do not contain as wide array of anthocyanins, including more structurally  
complex acylated forms found in many other berries  (Kaume et al., 2012; Wu and Prior, 
2005).  
Still, translation of such findings to dietary strategies to prevent chronic diseases is 
limited by several factors including the poor oral bioavailability of flavonoid compounds 
from food. Excluding microbial metabolites, less than 5% of a single acute oral, food-
based dose of flavonoids are commonly reported to be absorbed (Neilson and Ferruzzi, 
2011), though higher bioavailability values have been reported for ingestion of purified 
flavonoids (Manach et al., 2005). However, bioavailability from single oral doses, the 
most typically applied assessment of oral bioavailability, may not be indicative of the 
more common dietary paradigm of repeated daily exposure encountered by high 
consumers of fruits and vegetables. Evidence does exist that long-term exposure to 
flavonoids can significantly alter bioavailability (Chow et al., 2003; Ferruzzi et al., 2009) 
and metabolism of flavonoids (Wang et al., 2015, 2012). In an animal study, 10 day 
administration of a grape seed extract improved plasma response of catechin 
(C)/epicatechin (EC) (Ferruzzi et al., 2009) and C/EC glucuronides and methyl-
glucuronides (Wang et al., 2012). In addition, clinical work has demonstrated that 4 
week chronic daily administration of EGCG increased its AUC by approximately 60% 
(Chow et al., 2003).  
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While an adaptive response to phenolic chronic exposure has been observed in 
both pre-clinical and clinical models, the mechanisms behind this phenomenon are not 
well understood. Since dietary patterns typically result in a paradigm of chronic 
exposure to various phenolic compounds, there is a need to better understand the 
adaptive phenomena so they can be leveraged to improve bioavailability and delivery of 
key phenolic metabolites related to disease-preventative endpoints. Considering the 
gastrointestinal tract is the main barrier to delivering dietary phenolics systemically, we 
hypothesize that adaptation occurring in the upper gastrointestinal epithelium is a key 
factor modifying absorption of phenolics and may be responsible, in part, for the 
observed differences in flavonoid absorption and metabolism in chronic dosing 
paradigms.  
To gain a better mechanistic understanding of bioavailability, researchers have 
utilized differentiated Caco-2 cell monolayers to study transport of pharmaceuticals and 
phytochemicals since they are highly predictive of human absorption (Sambuy et al., 
2005). However, most studies involving the Caco-2 cell model are limited to acute 
experimental paradigms and do not consider how chronic exposure typical of dietary 
patterns modulates physiological activities, such as absorption at the gut epithelium. 
Since the Caco-2 model has exhibited differential transport of phenolics in acute versus 
a long-term treatment with grape-derived anthocyanins (Faria et al., 2009), we 
proposed simulating the chronic treatment paradigm from previous animal studies using 
Caco-2 cell monolayers to determine if we could model an adaptive response in 
transport of blackberry phenolics.    
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4.2 Materials and Methods 
4.2.1 Preparation of Blackberry extract 
Composite blackberry extract was produced from frozen blackberries, which 
were a combination of Rubus laciniatus, Rubus Marion, and Rubus fruticosus L. 
purchased from SYSCO (Houston, TX). Blackberries were freeze-dried and then extracted 
with methanol:H2O (80:20; v:v) and resulting extracts dried under a nitrogen stream. 
Bulk extract was then resoluabilized in H2O:HCl (99.9:0.01; v:v) and purified using an 
Extract Clean™ 10,000 mg/75 mL C18-HC column (Grace, Columbia, MD). Briefly, the 
column was activated with 1 column volume (75 mL) MeOH, followed by 3 column 
volumes H2O. Blackberry extract was loaded onto the column and successively washed 
with 4 column volumes H2O to remove ascorbic acid, sugars, and other osmotically 
active compounds, dried for 30 s with vacuum, and then eluted with 1 column volume 
of MeOH:HCl (99.9:0.01; v:v). The eluate was then aliquoted into glass tubes, dried 
under a nitrogen stream, and stored at -80°C until further use.  
 
4.2.2 Cell culture and treatments 
Caco-2 TC7 cell line (passages 81-84) was maintained in DMEM media with 10% 
FBS with 10% v/v FBS, 1% v/v nonessential amino acids, 1% v/v HEPES, 1% v/v 
penicillin/streptomycin, and 0.1% v/v gentamicin. Cells were seeded at a density of 2.12 
x 105  cells/cm2 on a Transwell® insert system (Corning® polyester membrane, 24 mm 
diameter, pore size 0.4 μm), and monolayers were differentiated over a period of 
approximately 25 d post-confluency. Total phenolic concentration of blackberry extract 
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was determined by the Folin-Ciocalteu total phenolic method (Waterhouse, 2001) and 
sterile filtered (0.2 μm filter). Cells were cultured in growth media with a final 
concentration of either 0 μM (control), 1 μM, or 10 μM blackberry phenolics, added to 
the apical chamber (see Figure 13 for outline of experimental design). Preliminary 
experiments showed that cell monolayers could be chronically treated with 10 μM of 
extract without significantly decreasing cell viability (>95%) as determined by MTT assay 
(Biotium, Hayward, CA). All growth media was changed every 48 h. 
 
Figure 13. Experimental design to simulate chronic treatment of Caco-2 cell monolayers. 
Cells were cultured in growth media with either 0 μM (control), 1 μM, or 10 μM of 
blackberry extract added to the apical chamber. After all cells were cultured in control 




4.2.3 Transport of Phenolic Compounds 
Before assessing transport of phenolics, cell monlayers were cultured for 24 h in 
control growth media, rinsed twice with 0.1% fatty-acid free albumin in PBS, and 
followed with PBS only. Transport of blackberry extract was assessed using an acute 
dose of 100 µM total phenolics in PBS transport buffer (pH = 5.5). 1.5 mL transport 
media was added to the apical chamber and 2 mL of PBS (pH = 5.5) was initially placed 
in the basolateral chamber, after which 1 mL PBS was collected and replaced with fresh 
PBS at 0 (immediately collected after transport media was loaded), 30, 60, 90, 120, and 
240 min. Experiments were performed in quadruplicate. After the 4 h uptake period, 
cells were rinsed according to the above procedure and then collected in ice cold PBS 
(pH = 5.5). Transport media was acidified with 1% v/v formic acid/acetonitrile and then 
left on ice for 10 min to precipitate protein, and centrifuged at 18,000 g for 5 min to 
remove particulates before injecting 20μL in the LC-MS-TOF system. Stability of 
compounds in transport media over 4 h was assessed by incubating cell-free transport 
media in 6-well plates, and recovery of cyanidin-3-O-glucoside in the media was found 
to be 98.1 ± 3.75% (mean ± SEM). 
  
4.2.4 Analysis of Blackberry Extract and Test/Transport Media 
Analysis of blackberry extracts and test/transport media was adapted from 
methods previously described (Song et al., 2013, 2015). Briefly, separations of phenolics 
was achieved using a Waters RP-C18 column (Xbridge BEH Shield, 2.5 µm, 2.1x100 mm) 
and characterized using an Agilent 1100 high-pressure liquid chromatography system in 
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tandem with a Waters LCT Premier time-of-flight mass spectrometer (LC-TOF-MS) with 
electrospray ionization (ESI) in either positive (for anthocyanins) or negative mode (for 
other phenolics). The flow was set to 0.25 mL/min and mobile phases were A: 2% formic 
acid (aq.); B: acetonitrile (0.1% formic acid) for anthocyanin analysis and A: 0.4% formic 
acid (aq.); B: acetonitrile (0.1% formic acid) for other phenolics. A linear gradient 
condition for eluting anthocyanins was as follows: initial conditions were 5% B; 0-15 min: 
5-25% B; 15-18 min: 25-30% B; 18-19 min: 30-5% B; 19-23.5 min: hold at 5% B to reset 
the gradient. Conditions for other phenolics was 5% B at 0 min; 0-15 min: 5%-35% B; 15-
17 min: 35-70% B; 17-19 min: 70-5% B; hold at 5% B at 23 min to reset the gradient. 
Mass-to-charge (m/z) ratios used to produce extracted ion chromatograms (EICs) and 
used to characterize and quantify compounds are displayed in Table 10. Cyanidin-3-O-
glucoside was characterized using MS and then quantified using photodiode array (PDA) 
response at 520 nm. Standard curves using pure standards of cyanidin-3-O-glucoside 
(Chromadex, Irvine, CA), (+)-catechin, (-)-epicatechin, quercetin-3-O-glucoside, 
kaempferol-7-O-glucoside, and 3-O-caffeoylquinic acid (Sigma, St. Louis, MO) were 
produced to quantify transported phenolics.  
 
4.2.5 Gene expression 
In order to determine alteration of xenobiotic transport and metabolizing system 
gene expression due to chronic exposure, a parallel set of Caco-2 cell experiments was 
conducted with cells treated as previously described in Section 2.2. RNA was isolated 
using RNeasy spin columns according to the manufacturer’s directions (Qiagen Sciences, 
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Germantown, MD). RNA was analyzed by Experion RNA gel electrophoresis (Bio-Rad 
Laboratories, Hercules, CA) for its quality and quantity, reverse transcribed to cDNA, and 
then plated onto the Drug Metabolism: Phase II Enzymes PCR Array (SABiosciences, 
Germantown, MD, catalogue no. PAHS-069Z) and the Drug Transporters PCR Array 
(SABiosciences, Germantown, MD, catalogue no. PAHS-070Z), following manufacturer’s 
instructions to determine alterations in expression of the respective genes. Real-time 
PCR was conducted using a CFX96 real-time PCR system (Bio-Rad laboratories). 
 
4.2.6 Data Analysis 
Values for phenolics are expressed as average pmol per well ± SEM (n = 4). The 
apparent permeability coefficient (Papp) was calculated using an equation previously 
reported using the Caco-2 cell model to measure transport of compounds through the 
cell monolayer (Hubatsch et al., 2007). Gene expression values are displayed as average 
(n = 3) ∆∆Ct fold-changes in mRNA expression relative to housekeeping genes. Displayed 
data were selected by determining genes with significant (P < 0.05) or near significant 
changes in expression. Analysis of gene expression data was performed using an Excel 
(Microsoft, Redmond, WA) spreadsheet template as provided by SABiosciences. All 
other analyses were performed using SAS 9.3 (SAS Institute, Cary, NC), and significant 





4.3.1 Differential transport of blackberry phenolics with pretreatment  
Phenolic composition of the extract is shown in Table 11. The main anthocyanin 
in the blackberry extract was cyanidin-3-O-glucoside, which corresponds to previously 
reported values (Kaume et al., 2012; Mertz et al., 2007). Interestingly, this blackberry 
preparation did have greater amounts of kaemperfol glycosides and less quercetin 
glucoside compared to previous reports (Mertz et al., 2007), but this may simply be due 
to differences between geographic origin, harvest season and specific variety. The 















Table 10. Mass-to-charge (m/z) ratios and ionization mode used to characterize phenolic 
compounds in treatment and transport media using LC-TOF-MS.  
Compound m/z Ionization mode 
Cyanidin-3-O-glucoside 449 + 
Catechin/Epicatechin 289 − 
Kaempferol glucoside 447 − 
Kaempferol glycoside  
derivative 465 − 
Quercetin glucoside 463 − 
Dicaffeoylquinic acid 515 − 
 
Since major phase II metabolites of the parent compounds found in the 
blackberry extract were not observed to a great extent in this model (data not shown), 
we focused on tracking the parent compounds for flux through the cell monolayers. 
Figure 14 displays cumulative apical to basolateral transport data for the seven major 
phenolic species in the blackberry transport media. After 2 h, 1 μM pretreated 
monolayers showed significant (P < 0.05) differences in transport including a 34% 
decrease in cumulative transport of cyanidin-3-O-glucoside compared to control (0 μM 
pretreatment) (7.14 vs. 4.75 nmol; 0 μM vs. 1 μM pretreatment) and 30% less transport 
of dicaffeoylquinic acid (6.61 vs. 4.64 nmol; 0 μM vs. 1 μM pretreatment). After 4 h, 1 
μM pretreated monolayers were observed to have reduced transport of every phenolic 
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compound other than cyanidin-3-O-glucoside including 33% less catechin (0.979 vs. 
0.654 nmol; 0 μM vs. 1 μM pretreatment), 42% less epicatechin (2.48 vs. 1.43 nmol; 0 
μM vs. 1 μM pretreatment), 19% less kaempferol glucoside (41.1 vs. 31.5 nmol; 0 μM vs. 
1 μM pretreatment), 23% kaempferol glycoside derivative (17.5 vs. 14.1; 0 μM vs. 1 μM 
pretreatment), 20% less quercetin glucoside (1.90  vs. 1.19; 0 μM vs. 1 μM 
pretreatment), and 30% less dicaffeoylquinic acid (20.9 vs. 14.2; 0 μM vs. 1 μM 
pretreatment). While there were no significant differences in phenolic transport over 4 
h with 10 μM pretreatment, it significantly (P < 0.05) exhibited decreased transport of 
kaempferol glucoside (15.2 vs. 12.2 nmol; 0 μM vs. 10 μM pretreatment) and 
dicaffeoylquinic acid (6.61 vs. 4.60; 0 μM vs. 10 μM pretreatment) over 2 h. In addition, 
a decrease in quercetin glucoside transport was observed after 90 min in the 10 μM 




Figure 14. Chronic pretreatment with blackberry fruit phenolics differentially alters 
apical to basolateral transport of blackberry fruit phenolics across differentiated Caco-2 
cell monolayers. Confluent Caco-2 monolayers were cultured on Transwell® inserts in 
pretreatment (PT) media containing either 0 (control), 1, or 10 µM total blackberry 
phenolics (see table 2 for composition of blackberry transport media) during the 
differentiation process. All cell monolayers were incubated with control media 24 h 
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(Figure 14 caption, con’d) before transport was assessed using a 100 µM acute dose of 
total blackberry phenolics over 4 h. Left panel displays uptake data over 2 h while right 
panel is over 4 h. Statistical pairwise comparison was performed comparing 0 (control) 
to 1 or 10 µM PT. *P < 0.05 compared to control. Abbreviations: PT, pretreatment; Cy-3-
glc, cyanidin-3-O-glucoside; C, catechin; EC, epicatechin; K-glc, kaempferol glucoside; K-
gly, kaempferol glycoside derivative; Q-glc, quercetin glucoside; DCQA, dicaffeoyquinic 
acid. 
 
Table 11. Blackberry Transport Loading Media phenolic Composition (100 μM total 
phenolics)a  
Phenolic class Compound μM ± SD 
Anthocyanin Cyanidin-3-O-glucoside 37.70 ± 1.05 
Flavan-3-ols 
Catechin 0.230 ± 0.0213 
Epicatechin 3.339 ± 0.107 
Flavonols 
Kaempferol glucoside 13.119 ± 0.779 
Kaempferol glycoside 
derivative 8.314 ± 0.258 
Quercetin glucoside 2.34 ± 0.14 
Phenolic acid Dicaffeoylquinic acid 19.80 ± 0.255 
 
TOTAL 84.73 








Table 12. Apparent permeability coefficients (Papp) of blackberry phenolics across differentiated Caco-2 cell monolayers.a 
Compound Pretreatment log Papp (cm/s) over 2 h log Papp (cm/s) over 4 h 
Cyanidin-3-O-glucoside 
0 µM -7.26 ± 0.855 -6.82 ± 0.846 
1 µM -7.38  ± 0.875** -6.85 ± 0.820  
10 µM -7.36 ± 0.856* -6.77 ± 0.778 
Catechin 
0 µM -6.33 ± 0.740 -6.18 ± 0.761 
1 µM -6.33 ± 0.744 -6.34 ± 0.760** 
10 µM -6.36 ± 0.713 -6.25 ± 0.726# 
Epicatechin 
0 µM -6.97 ± 0.808 -6.77 ± 0.802 
1 µM -7.00 ± 0.837 -6.91 ± 0.816** 
10 µM -7.03 ± 0.773 -6.79 ± 0.801 
Kaempferol glucoside 
0 µM -6.44 ± 0.761 -6.31 ± 0.757 
1 µM -6.55 ± 0.790* -6.42 ± 0.772* 
10 µM -6.57 ± 0.774* -6.32 ± 0.765 
Kaempferol glycoside derivative 
0 µM -6.55 ± 0.771 -6.48 ± 0.785 
1 µM -6.57 ± 0.799 -6.57 ± 0.785* 
10 µM -6.63 ± 0.805* -6.49 ± 0.799 
Quercetin glucoside 
0 µM -7.10 ± 0.794 -7.30 ± 0.754 
1 µM -7.64 ± 0.787* -7.49 ± 0.775 
10 µM -7.64 ± 0.791* -7.25 ± 0.749 
Dicaffeoyquinic acid 
0 µM -6.97 ± 0.783 -6.78 ± 0.801 
1 µM -7.17 ± 0.831* -6.92 ± 0.801* 
10 µM -7.17 ± 0.857* -6.83 ± 0.811 
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Table 12 legend.  
a) Values are presented as average (n = 4) ± SEM. Statistical pairwise comparison is 
between pretreatments and 0 µM. 
 *P<0.05; **P<0.01; #P=0.0503. 
 
Iterestingly, phenolics were not detectable in cell monolayers after 4 h exposure to any 
treatment.  
Table 12 displays transport data as log apparent permeability (Papp) calculated 
from the rate of each phenolic’s transcellular flux. While log Papp of cyanidin-3-O-
glucoside was not affected over 4 h, both pretreatment conditions significantly (P < 0.05) 
decreased its log Papp over 2 h from -7.26 cm/s for 0 μM pretreated to -7.38 and -7.36 
cm/s for 1 and 10 μM pretreatment, respectively. For flavan-3-ols catechin and 
epicatechin, log Papp significantly decreased over 4 h and not 2 h for the 1 μM 
pretreatment and reached near significance (P = 0.0503) for catechin transport over 4 h. 
For flavonols, kampferol glucoside showed decreased log Papp for both treatments over 
2 h but only 1 μM treatment over 4 h, and similar results were found for the kaempferol 
glycoside derivative. Quercetin glucoside exhibited significantly decreased log Papp for 
both treatments at 2 h but not 4 h. Lastly, dicaffeoyquinic acid showed decreased log 
Papp for both treatments over 2 h but only 1 μM pretreatment reached statistical 




4.3.2 Differential changes in mRNA expression of xenobiotic transport and 
metabolizing systems 
Figure 15 displays alterations in expression of xenobiotic metabolizing system 
genes with 4 h 100 μM acute treatment only and 10 μM pretreatment plus 100 μM 
acute treatment compared to differentiated cell monolayers. These data show 
significant (P < 0.05) alterations in gene expression related to Phase II metabolism 
including methylation, sulfation, and glucuronidation for both treatments. However, six 
out of the 15 genes displayed in Figure 15 were significantly (P < 0.05) different only 
with pretreatment in contrast to cell monolayers solely receiving acute treatment. The 
results showed increased expression of one of the three genes UGTs (UGT2B10), while 
there was decreased expression of both UGT1A4 and UGT1A8. Gene expression was 
altered in four SULT genes, with pretreatment alone resulting in a significant decrease in 
SULT2A1 expression. SULT4A1 expression decreased to a greater magnitude with 
pretreatment (-4.5 fold) compared to acute treatment only (-1.6 fold). Three 
methylation genes (GNMT, HNMT, and TPMT) were significantly altered from the 
treatments, but GNMT was only altered with pretreatment.  
Figure 16 displays transport genes whose expression was impacted by both the 
acute and chronic treatments. Eight out of the 15 transporters displayed were only 
significantly (P < 0.05) affected by pretreatment plus acute treatment. Overall, there 
was decreased expression of transport systems except SLC7A11, which significantly 







Figure 15. Differential alteration in gene expression of Phase II metabolizing enzymes in 
differentiated Caco-2 cells due to chronic pretreatment (PT) compared to acute only 
treatment with blackberry fruit extract. Values are displayed as average (n = 3) ∆∆Ct 
fold-changes in mRNA expression relative to selected housekeeping genes. Statistical 
pairwise comparison was performed comparing differentiated Caco-2 cells to 













Figure 16. Differential alteration in gene expression of transport systems in 
differentiated Caco-2 cells due to chronic pretreatment compared to acute only 
treatment with blackberry fruit extract. Values are displayed as average (n = 3) ∆∆Ct 
fold-changes in mRNA expression relative to selected housekeeping genes. Statistical 
pairwise comparison was performed comparing differentiated Caco-2 cells to 




The Caco-2 cell model has been previously used to elucidate mechanism of 
absorption and metabolism for phenolics connected by epidemiological associations 
between berry consumption and reduced risk of chronic disease. Caco-2 experiments 
have demonstrated that blackberries and other berries rich in anthocyanins have been 
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characterized to have effects including decreased peroxyl radical production (Elisia and 
Kitts, 2008) to decreased gene expression of GLUT2 and SGLT1 (Alzaid et al., 2013). In 
addition, the three compartment Caco-2 cell model used in this study has been widely 
utilized to assess intestinal transport of flavonoids and phenolic acids from various berry 
extracts and has also been done in parallel to clinical studies (Kuntz et al., 2015). 
However, characterization of the effect of chronic exposures that mimic dietary patters 
rich in berry foods on phenolic transport and metabolism is limited. Since intestinal 
enterocytes have a high turnover rate and the nascent cells repopulating the epithelial 
lining are influenced by the extracellular matrix (Reya and Clevers, 2005), it is possible 
that dietary factors including phenolics can influence the differentiating cell’s function. 
Supporting this notion are data demonstrating that Caco-2 monolayers chronically 
treated with extracts of grape seed and grape products during the differentiation 
process exhibit altered markers of differentiation such as sucrase-isomaltase and 
aminopeptidase N (Laurent et al., 2004, 2005), suggesting that the addition of phenolic-
rich extracts to cellular media is fundamentally altering the cell’s phenotype. 
Our data overall show significant (P < 0.05) decreases in the cumulative transport 
of phenolic compounds across Caco-2 cell monolayers with pretreatment of berry 
extracts in a fashion that mimics the exposure of a chronic dietary pattern rich in berries. 
This is in contrast to Faria et al. which showed an approximately 50% increase in 
transport of anthocyanins with 96 h pretreatment of phenolic-rich grape skin extract 
before assessing transport in Caco-2 cells (Faria et al., 2009).  Additionally, these results 
differ from animal work done with grape seed extract rich in flavan-3-ols (Ferruzzi et al., 
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2009; Wang et al., 2012) and a human study that administered isolated EGCG (Chow et 
al., 2003), which both reported increased bioavailability with chronic exposure. There 
are likely several reasons for these differences, one being that Faria et al. pretreated 
Caco-2 monolayers with ≈400 µM phenolics (200 µg/mL grape skin anthocyanins), and 
the animal and clinical study would have produced concentrations in the gut lumen 
estimated to be ≈4.3 mM and ≈900 µM, respectively. While it is possible that luminal 
concentration of flavonoids would be higher from typical servings of foods (Scalbert and 
Williamson, 2000), relatively low doses were chosen here (1-10 µM) based on 
preliminary screening of cytotoxicity and to mimic more modest concentrations 
achieved by typical consumption of fruits in the U.S. (approximately 100 g per day) for 
both children (Kim et al., 2014) and adults (Kimmons et al., 2009). Thus, use of these 
relatively lower concentrations in the current study may partially explain the differences 
in the directionality of the observed changes in transport between animal studies and 
preclinical cell-based studies here. 
Other differences between this study and others assessing phenolic transport 
include our use of anthocyanin-rich blackberry extract, which contains a different milieu 
of phenolic compounds than those used previously, suggesting that intestinal 
adaptation may be dependent on phenolic class and matrix. Additionally, since Caco-2 is 
a human intestinal cell line, it is not unexpected for the data to be somewhat different 
from animal models. Another consideration for our results is that phenolic extracts were 
used in order to isolate the effect of phenolic compounds over non-phenolic compounds 
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such as ascorbic acid and sugars, which have both been reported to increase 




Figure 17. Enterocyte localization of transport proteins affected by blackberry extract 
treatments and directional change of its mRNA expression.  
 
 
There appeared to be greater alteration in transport over 4 h from 1 μM but not 
10 μM pretreated monolayers (see Figure 16), which demonstrates that it is critical to 
assess transport over a range of time points. The decreases in log Papp values with 
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chronic exposure (Table 12) indicates that there may be less absorption of these 
compounds in vivo with pretreatment since log Papp values have been reported to 
correlate with the fractional absorption of select pharmaceutical compounds in humans 
(Hubatsch et al., 2007). As such, this decrease in log Papp values may therefore indicate 
decreased intestinal transport with chronic exposure in a clinical setting. Since phenolics 
were not detectable in cell monolayers in any treatment group, differences in transport 
are likely not due to increased cellular accumulation. 
 Our data showed differences in gene expression of the Phase II metabolizing 
enzymes with blackberry exposure. We observed significant (P < 0.05) decreases in 
mRNA expression of Phase II metabolizing enzymes UGT1A4 and borderline significant 
(P = 0.0501) decreased expression of UGT1A8 with pretreatment (see Figure 15). This 
decrease may be due to the large concentration of glycosylated compounds (for 
example, anthocyanin and flavonol glycosides) present in blackberry extract, since 
phenolic glycosides have been reported to reduce circulating glucuronidated 
metabolites in rodent models and decrease gene expression of UGT1A8 in rat intestinal 
tissue (Ma et al., 2013). As such, decreasing glucuronidation systems in the intestine 
may shift xenobiotic metabolism to other tissues such as the liver and kidney. Still, 
mRNA expression of other Phase II metabolizing enzymes show increased expression 
(such as sulfotransferases and methylation enzymes) apparently due to the inducible 
nature of these systems. Though Phase II metabolites of the flavan-3-ols have been 
reported in Caco-2 cell model (Rodriguez-Mateos et al., 2014; Zhang et al., 2004), we 
were unable to detect metabolites, which may be related to their concentrations being 
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under the limit of detection of our instrumentation or due to the use of complex plant 
extracts rather than isolated phenolics used in previous studies.      
Overall, gene expression of transport systems decreased, except for the amino 
acid transporter SLC7A11, which increased by more than four-fold (Figure 16). These 
decreases in gene expression may partially account for the observed lower cumulative 
phenolic transport. Though GLUT2 (SLC2A2) and SGLT1 (SLC5A1) have been shown to be 
critical to the absorption of cyanidin-3-O-glucoside in the Caco-2 model (Zou et al., 
2014), these transporters were not significantly affected by treatments and may explain 
why transport of this compound was only modestly affected. In addition, gene 
expression was only measured after the 4 h acute treatment period, which may have 
not captured any differences occurring before this time interval. Localization of these 
transporters is also an important factor to consider (see Figure 17) in addition to 
molecular interaction of transporters with phenolic compounds, which may not 
necessarily be accounted for by gene expression data. 
Interestingly, transepithelial electrical resistance (TEER) values significantly (P < 
0.05) increased in 10 μM but not 1 μM pretreated monolayers (Table 13), which may 
indicate that gut barrier function may be altered through pretreatment by increasing 
tight junction proteins. Since the TEER values in 1 μM pretreated monolayers were not 
significantly different (P > 0.05) from control, observed differences in transport are likely 
due to changes in transport-mediated and not paracellular mechanisms. Apple extracts 
have been reported to increase TEER values in Caco-2 cell monolayers (Vreeburg et al., 
2012), along with quercetin (Amasheh et al., 2008).and naringenin (Noda et al., 2013), 
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which both upregulate gap junction proteins. In addition to cell culture studies, this 
increase in levels of tight junction proteins has similarly been shown in animal models 
treated with flavan-3-ol rich grape seed extract (Goodrich et al., 2012).   
 
Table 13. Background-subtracted transepithelial electrical resistance (TEER) values of 
differentiated Caco-2 cell monolayers used in transport experiments.a 
Pretreatment Condition TEER (Ω∙cm2) 
0 µM 240 ± 4.74a 
1 µM 240 ± 7.46a 
10 µM 256 ± 4.37b 
a) Values are presented as average (n = 4) ± SEM, and those with different letters are 




One limitation of this model is that it does not consider other tissues involved in 
transport and metabolism of phenolics, such as the liver. Primary hepatocytes exhibit 
altered expression of organic anion transporting polypeptides (OATPs) with longer-term 
exposure (24 h) to select isolated anthocyanins (Riha et al., 2015), indicating that this 
tissue needs to be considered for future work. In addition, the Caco-2 model only 
focuses on adaptation occurring in the upper gut, which does not consider alterations in 
gut microbiota that may occur with a diet high in phenolics. Berries have been shown to 
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influence gut microbiota in animal (Jakobsdottir et al., 2013; Lacombe et al., 2013) and 
human (Vendrame et al., 2011) studies. Further, the gut microbiome has been 
reportedly modified by repeated exposure to phenolic-rich grape seed extract, leading 
to increased production of low-molecular weight phenolic catabolites with potential 
bioactive effects (Wang et al., 2015).  
 
4.5 Conclusion 
Our data show there was an adaptive response in the Caco-2 cell model 
following a pretreatment period, demonstrating this model is dynamic and may be used 
for mechanistic insight into gut physiological responses. Decreased transport of 
blackberry phenolics were observed with pretreatment, suggesting that chronic 
exposure led to decreased flux through the cell or possibly shifts in metabolism of 
phenolics. We also observed changes in expression of xenobiotic transport and 
metabolism genes with chronic exposure to blackberry extract that were consistent with 
the observed decreased transport of phenolic compounds. Although the transport data 
in this study did not appear to correlate to previous animal and clinical studies, this may 
be due to differences in phenolic class and matrix of the tested extract. Future studies 
should consider exploring methods to develop a model that incorporates other aspects 
of human physiology affected by chronic exposure to phenolics, such as the liver and the 
gut microbiome. Taken together, these results suggest that intestinal xenobiotic 
transport and metabolism are modulated by chronic exposure to phenolic-rich 
blackberry extract. Overall, these results indicate that adaptation occurring to the 
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intestinal epithelium with chronic exposure to phenolic compounds is critical to consider 
for a variety of implications involving absorption. As such, studies assessing 
bioavailability with only an acute dose may not be readily translational due to 







CHAPTER 5. EFFECT OF 3-WEEK BLACKBERRY REPEATED EXPOSURE ON THE 
ABSORPTION, METABOLISM, AND EXCRETION OF FLAVONOIDS IN LEAN AND OBESE 
HUMANS 
5.1 INTRODUCTION 
Increased consumption of berry fruits has been associated with a reduced 
incidence of certain chronic diseases, such as heart disease and type 2 diabetes (Cassidy 
et al., 2013; Muraki et al., 2013). Supporting these associations are clinical studies 
linking improvements in markers of heart disease and oxidative stress to berry 
consumption (Del Bo’ et al., 2015). Specifically, consumption of blueberry, cranberry and 
strawberry have all been reported to improve risk factors for cardiovascular disease 
such as high blood pressure, oxidized LDL, lipid peroxidation, and low HDL 
concentrations (Basu et al., 2010, 2014; Ruel et al., 2008). Though the mechanism of 
action involved in how the components in berries impart their observed beneficial 
effects is still a topic of much investigation, it is known that that berries are a rich 
dietary source of flavonoids, especially the pigmented anthocyanins, which have been 
hypothesized to be involved in exerting their biological activity.  
Though not as heavily researched as the aforementioned berries, there is 
substantial in vitro work suggesting that blackberry can help prevent risk factors thought 
to be involved in cancer and heart disease, such as oxidized lipoproteins and nucleic 
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acids (Kaume et al., 2012). In pre-clinical rodent models, blackberry has been 
reported to have effects ranging from prevention of bone loss (Kaume et al., 2015) to 
decreased systemic blood glucose concentrations (Stefănuţ et al., 2013), while clinically 
it may improve risk factors for cardiovascular disease in dyslipidemic populations 
(Aghababaee et al., 2015). Since flavonoids appear to have strong potential as the 
mediators of the observed beneficial effects of berry consumption, it is critical to fully 
understand factors that influence or alter the absorption and excretion of these 
compounds, especially in the context of long-term dietary patterns that more closely 
resemble those linked to epidemiological associations.  
While promising, application of berry-derived anthocyanins and other flavonoids 
for use in disease preventative strategies is limited by the notion that, excluding 
microbial metabolites, the acute oral bioavailability of intact flavonoids is less than 5% 
(Neilson and Ferruzzi, 2011). However, it is important to note that pharmacokinetic 
assessments commonly reported for flavonoids and used in of determining their 
bioavailability are typically performed using a single acute dose which is not 
representative of the chronic exposure resulting from broad dietary patterns. Indeed, 
both clinical and pre-clinical research has demonstrated that repeated exposure to 
flavonoids in a longer-term fashion resembling daily consumption dietary patterns may 
alter bioavailability of these compounds. For example, ten-day repeated administration 
of a grape seed extract product in rodents improved plasma response of catechin and 
epicatechin by greater than approximately 150% (Ferruzzi et al., 2009; Wang et al., 
2012). Four-week daily administration of 800 mg of the flavan-3-ol epigallocatechin 
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gallate (EGCG) per day before an acute pharmacokinetic assessment resulted in plasma 
EGCG AUC values approximately 60% greater compared to those not repeatedly 
exposed to EGCG. Considering this potential for adaptation, a more complete 
understanding of factors driving this effect from whole foods, such as berries, is critical 
to best leverage this phenomenon for therapeutic endpoints.  
In addition, due to the increasing prevalence of obesity on a global level (Ogden et 
al., 2007), it is important to consider how this condition may affect bioavailability of 
flavonoids and their specific metabolites. This information is critical to develop targeted 
dietary recommendations for these population groups. Certain factors associated with 
obesity have been implicated in possibly altering the bioavailability or bioactivity of 
these compounds (Xiao and Högger, 2014), including alteration of gut function and 
modulated gut bacterial populations that may affect production of various bioactive 
metabolites (Selma et al., 2015). Additionally, obesity has been associated with 
decreased status of both fat-soluble (vitamin K, β-carotene and tocopherol) and water-
soluble micronutrients (folate), suggesting that increased BMI may affect absorption 
and/or metabolism of dietary compounds (Mahabir et al., 2008; Shea et al., 2010; Wise 
et al., 2009). In order to better understand adaptation to repeated berry exposure in 
lean and obese participants, the present study tested whether 3-week repeated daily 
exposure to blackberries elicits an adaptive response in the absorption and/or excretion 
of flavonoids as assayed by a seven-hour pharmacokinetic challenge. We hypothesized 
that there would be an adaptive response in the absorption and excretion of flavonoids 
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with repeated exposure to blackberry and that this response will differ between lean 
and obese groups volunteers. 
  
5.2 Materials and Methods 
 
5.2.1 Reagents 
Analytical standards of cyanidin-3-O-glucoside (Chromadex, Irvine, CA), 
epicatechin, and kaempferol-7-O-glucoside (Sigma, St. Louis, MO) were obtained. 
Solvents for LC-MS/MS were of mass spectrometry grade and all solvents were at least 
analytical grade. Formic acid and triflouroacetic acid were obtained from Sigma-Aldrich 
(St. Louis, MO). 
 
5.2.2 Experimental study design and diets 
This randomized, controlled, cross-over design study was conducted at the USDA 
Beltsville Human Nutrition Research Center (BHNRC; registered at ClinicalTrials.gov#: 
NCT01944579). This study (see Figure 19 for study design) received IRB approval (see 
Appendix C), and participants provided written informed consent. Inclusion criteria 
included those 25-75 years old. Exclusion criteria included: individuals using blood-
thinning medications, presence of any gastrointestinal disease, metabolic disease, or 
malabsorption syndromes, pregnancy during the previous 12 months, are currently 
pregnant or lactating, or plan to become pregnant during the study, Type 2 diabetes 
requiring the use of oral antidiabetic agents or insulin, fasting triglycerides greater than 
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300 mg/dL, fasting glucose greater than 126 mg/d, use of prescription or over-the-
counter antiobesity medications or supplements during and for at least 6 months prior 
to the start of the study or a history of a surgical intervention for obesity, active 
cardiovascular disease, use of any tobacco products in past 3 months, unwillingness to 
abstain from herbal supplements for two weeks prior to the study and during the study, 
and known (self-reported) allergy or adverse reaction to blackberries or other study 
foods. Participants were provided a controlled diet generated by a registered dietitian 
during the length of the study to maintain weight and to provide dietary flavonoids from 
blackberry (See Table 14 for detailed meal composition and Figure 18 for macronutrient 
composition). Each diet provided approximately 15% energy as protein, 30% energy as 
fat, and 55% energy as carbohydrate. Breakfast and dinner meals were required to be 
consumed under staff supervision at the research center on weekdays. Blackberries 
were a combination of Rubus laciniatus, Rubus Marion, and Rubus fruticosus L. 
purchased from SYSCO (Houston, TX). A total of 18 participants including individuals 
with normal BMI (n = 7, BMI 20-25) and an obese BMI (n = 11, BMI > 30) were fed a 
controlled diet that included either 300 g/d blackberries total, split between breakfast 
and dinner meals (treatment) or an isocaloric amount of gelatin (272 g) as the control. 
Treatment order was randomized, with half of the participants receiving the control 
treatment first over three weeks and the other half blackberries first over three weeks. 
A three-week washout period where the participants were instructed to avoid berries 
was between treatments. Each participant received the same lot of berries during the 






Table 14. Example meal composition of a typical day’s diet provided to participants.a 
a) “L” indicates the various “levels” of energy amounts provided to participants to 

















5.2.3 Pharmacokinetic (PK) assessment  
In order to determine the effect of repeated blackberry exposure on flavonoid 
bioavailability and metabolism, a pharmacokinetic (PK) assessment was conducted both 
three weeks after the participants received the control diet and three weeks after 
consuming the diet supplemented with blackberry. During the day of the PK assessment, 
volunteers arrived at the beginning of the day at the facilities fasted, produced a 
baseline urine, and then consumed 300 g blackberry homogenate within 5 min. Low-
flavonoid meals were provided at lunch at dinner times. Blood draws were performed at 
0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7 h and urine was collected at 0, 1.5, 3, 4.5, 6, and 7 
h. After blood was centrifuged at 2560 g for 10 min, 1 mL aliquot of plasma collected 
and stabilized with 0.6mL of 0.44 M triflouroacetic acid for anthocyanin analysis, and 
another 1 mL plasma aliquot was stabilized with 1% ascorbic acid for flavan-3-ols and 









Figure 19. Experimental study design for blackberry clinical trial. Lean (BMI 20-25; n = 7) 
and obese (BMI > 30; n = 11) participants were recruited for a randomized, cross-over, 
controlled feeding study to assess flavonoid pharmacokinetics after a three-week 
control period and after a three-week period with 150 g blackberries provided at both 
breakfast and dinner meals. A washout period where the participants were instructed to 
avoid berries was included between treatments. Pharmacokinetics were assessed from 
0-7 h after being placed on a controlled feeding regiment for three weeks containing 
either 277 g berry-flavored gelatin (control) or 300 g blackberries daily (containing an 
average of 753 mg flavonoids). Plasma and urine were collected during the 
pharmacokinetic challenge and analyzed by LC-MS/MS.  
 
5.2.4 Solid phase extraction (SPE) 
5.2.4.1 Anthocyanin SPE 
Solid phase extraction (SPE) for flavonoids was performed as previously reported 
with some modification (Blount et al., 2015). For plasma anthocyanin analysis, 1 mL 
plasma was loaded onto a 30 mg Oasis HLB cartridge (Waters Co., Milford, MA) that was 
activated with 3 mL MeOH followed by 3 mL H2O. The cartridge was then washed with 2 
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mL of 2% formic acid:H2O (v:v), then 1 mL 95:5 H2O:MeOH (v:v), and was finally eluted 
with 2 mL 2% formic acid:MeOH (v:v). 10 μL of 10 μM ethyl gallate was added to the 
eluate as an internal standard for MS, and this was dried under vacuum (< 50 mm Hg) at 
37°C. Residuals were then resolubilized in 100 μL of 2% formic acid:H2O (v:v), sonicated 
and vortex-mixed for 10 s each, and then centrifuged at 18,000 g for 5 min before 
supernatant was transferred to a 300 µL HPLC vial for analysis. Extraction recovery was 
assessed using ethyl gallate and was found to be greater than 95%. 
For urine analysis, 10 mL urine was centrifuged for 2 min at 2,000 g to remove 
particulates and was then loaded onto a 150 mg Oasis HLB cartridge (Waters, Milford, 
MA) that was activated with 6 mL MeOH followed by 6 mL H2O. This was followed by 
the cartridge being washed with 4 mL of 2% formic acid:H2O (v:v), 2 mL 95:5 H2O:MeOH 
(v:v), and then eluted with 4 mL 2% formic acid:meOH (v:v). 50 μL of 10 μM ethyl gallate 
was then added to eluate as an internal standard for MS and was dried under vacuum. 
Residuals were then resolubilized as above and centrifuged at 18,000 g for 10 min.   
5.2.4.2 Flavan-3-ols and Flavonols SPE 
SPE of plasma containing flavan-3-ols and flavonols was the similar as above with 
some modification. After plasma was loaded onto a cartridge activated with 1 mL MeOH 
followed by 1 mL H2O, the cartridge was washed with 1 mL of 1.5 M formic acid:H2O 
(v:v), 1 mL 95:5 H2O:MeOH (v:v), and then was eluted with 2 mL 0.1% formic acid:MeOH 
(v:v). Ethyl gallate internal standard was added to the eluate and dried under vacuum. 
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Residuals were then resolubilized in 160 μL of 0.1% formic acid:H2O (v:v) + 40 μL of 0.1% 
formic acid:ACN (v:v) before continuing procedure as in the section above.  
For urine analysis, SPE procedure was identical as the section above except for a few 
modifications. 10 mL urine was loaded onto a 150 mg Oasis HLB cartridge that was 
activated with 5 mL MeOH followed by 5 mL H2O. The cartridge was then washed with 2 
mL of 1.5 M formic acid, 5 mL 95:5 H2O:MeOH (v:v), and then was eluted with 4 mL 2% 
formic acid:MeOH (v:v). Ethyl gallate internal standard was added to the eluate and 
then dried under vacuum.  
 
5.2.5 LC-MS/MS analysis 
Biological samples were initially screened for a various parent compounds and 
their methyl, sulfate, and glucuronide metabolites, after which the major metabolites 
were followed.  
5.2.5.1 Anthocyanin analysis 
Parent compounds and metabolites were separated using an Agilent 1200 HPLC 
system using a Waters XBridge BEH shield RP-C18 XP 2.1 x 100 mm 2.5µm column 
following a 2 µm frit filter. The column and autosampler were maintained at 40 °C and 
10 °C, respectively. The flow was set to 0.26 mL/min and mobile phases were A: 2% 
formic acid (aq.); B: 0.1% formic acid/acetonitrile. Gradient conditions were 5% B at 0 
min, 25% B at 15 min, 30% B at 18 min, 5% B at 19 min, and 5% B at 23.5 min to reset 
the gradient.  
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5.2.5.2 Flavan-3-ol and flavonol analysis 
Flavan-3-ols and flavonols were analyzed similarly as anthocyanins except for a 
few differences. Compounds were analyzed in negative mode and different 
chromatography conditions are as follows. The flow was set to 0.26 mL/min and mobile 
phases were A: 0.1% formic acid (aq.); B: 0.1% formic acid/acetonitrile. Gradient 
conditions were 5% B at 0 min, 60% B at 10 min, 95% B at 11 min, 5% B at 12 min, and 
hold at 5% B at 22 min to reset the gradient. 
 
5.2.6 LC-MS/MS for flavonoid quantification  
Analytes were quantified using liquid chromatography with tandem mass 
spectrometry (LS-MS/MS) using an Agilent 6460 triple quadrupole with electrospray 
ionization (ESI) operated in negative mode using selected reaction monitoring (SRM) 
mass transitions. Injection volume was 10 μL for plasma and 5 μL for urine samples.  
Acquisition SRMs for all analytes are listed in Table 15. In addition, both methods 
had an SRM for ethyl gallate in negative mode, 197 → 169 m/z for use as an internal 
standard for MS. All mass transitions used a dwell time of 200 ms and fragmentor 
voltage of 135 V, and collision energy of 17 eV. Source parameters were as follows:  gas 
temperature = 350 °C, gas flow = 11 L/min, nebulizer pressure = 30 psi, sheath gas 
temperature = 350 °C, sheath gas flow = 11 L/min, capillary potential = 3500 V, and 




5.2.7 Limit of detection and quantification 
Limit of detection (LOD) was defined as signal-to-noise ratio (S/N) = 3 and limit of 
quantification (LOQ) as S/N = 9. LOD for cyanidin-3-O-glc, epicatechin, kaempferol-7-O-
glucoside, and quercetin-3-O-glucoside were 0.24 nM, 22.9 nM, 5.1 nM, and 1.5 nM, 
respectively. LOQ was 0.72 nM, 68.7 nM, 15.3 nM, and 4.5 nM, respectively. Both values 
were obtained by producing serial dilutions of the analyte. Signal-to-noise (S/N) ratio 
was calculated using MassHunter software using the peak-to-peak method. 
 
Table 15. Acquisition SRMs for LC-MS/MS. 
Compound MS1 MS2 mode 
Peonidin-glucur 477 301 + 
Cyanidin-glucur 463 287 + 
Peonidin-glc 463 301 + 
Cyanidin-3-O-glc 449 287 + 
EC-3’-O-glucr 465 289 - 
Kaemp-glucr 461 285 - 
Kaemp-7-O-glc 447 285 - 




5.2.8 Data analysis 
Plasma AUC is expressed as nmol compound∙h and was normalized to body 
weight and blood volume. Normal physiological parameters (blood volume/body weight) 
vary for obese patients, so an adjusted calculation was used in this case (Lemmens et al., 
2006). Urinary accumulation is expressed at cumulative nmol compound. Since different 
lots of blackberries were used throughout the study, data were also normalized on the 
basis of flavonoid dose. In addition, a carryover subtraction was performed as to 
eliminate bias due to accumulation of flavonoids throughout the blackberry treatment 
period. Any non-normally distributed data (as determined by the goodness-of-fit test) 
was transformed using the optimum lambda Box-Cox value, after which normality was 
again tested. Statistical significance was then determined using a paired t-test. Analysis 




5.3.1 Key flavonoid composition of blackberries 
Phenolic composition of blackberries is shown in Table 16. The main anthocyanin 
in the blackberries was cyanidin-3-O-glucoside, which is consistent with previous reports 
(Kaume et al., 2012; Mertz et al., 2007). Interestingly, the blackberries used in this study 
contained greater amounts of kaemperfol glycosides and less quercetin glycosides 
compared to previous reports (Mertz et al., 2007), but this variation may be related to 
differences in the specific varieties and harvest season.  
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5.3.2 Characterization of parent flavonoids and metabolites 
Figure 20 displays representative chromatograms of anthocyanins and their 
metabolites. In addition to the unmetabolized cyanidin-3-O-glc being identified, methyl 
and glucuronide derivatives were also detected. Since native peonidin was not detected 
to any great extent in blackberry, the peonidin in circulation is most likely derived from 
methylation of cyanidin by Phase II metabolizing systems, such as catechol-O-
methyltransferase (COMT). In addition, the presence of the two unresolved peaks likely 
indicates methylation at two different sites on the anthocyanin structural backbone.  
Figure 21 shows representative chromatograms of flavan-3-ols, flavonols and 
their metabolites. As with the anthocyanins, both methyl and glucuronide derivatives of 
kaempferol were detected. Presence of epicatechin-3’-O-glucuronide in urine and 
plasma was confirmed by comparing retention times to an authentic standard 











Table 16. Composition of key blackberry flavonoids from an example batch.a 
 
Cy-3-O-glc Catechin Epicatechin Kaemp-7-O-glc Quercetin-gly 1 Quercetin-gly 2 
Batch ug/g fresh weight 
A 932 ± 48.4 111 ± 7.22 638 ± 43.1 1440 ± 68.3 112 ± 4.66 45.0 ± 2.01 
B 585 ± 14.1 135 ± 2.09 637 ± 22.3 910 ± 22.6 54.9 ± 2.18 38.1 ± 1.41 
C 555 ± 45.4 157 ± 9.25 739 ± 59.2 919 ± 63.2 75.2 ± 5.15 44.9 ± 3.19 
D 322 ± 10.9 45.9 ± 2.60 237 ± 13.5 477 ± 28.7 108 ± 6.13 51.2 ± 2.52 
E 617 ± 2.16 99.1 ± 3.98 1100 ± 14.1 982 ± 6.30 87.1 ± 0.362 45.3 ± 7.37 
AVG 602 219 670 886 87.4 44.9 
aValues are expressed average ± SEM (n = 3). 
 
 
5.3.3 Plasma flavonoid AUC 
Figure 22 displays the absorption, metabolism, and excretion of select 
anthocyanins detected in plasma over 7 h after a bolus dose of blackberries. Overall, 
repeated blackberry treatment appeared alter the absorption and metabolism of select 
anthocyanins as indicated by differences in plasma AUC. In comparing specific 
treatments, the results showed that there was a statistically significant (P < 0.05) 
increase in plasma AUC of peonidin-glc 1 after 3-week blackberry treatment in lean but 
not obese participants. Pooling results from peonidin-glc 1 plus 2 plasma AUC, there was 
a borderline (P = 0.056) significant increase in these compounds for lean but not obese 
participants after blackberry treatment. In comparing differences in flavonoid plasma 
AUC due to BMI, a trend (P = 0.099) was observed for greater amounts of plasma 
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peonidin-glc 1 in the lean but not obese group after being exposed to blackberry. There 
was a stronger trend for the lean group containing higher amounts of cyanidin-3-O-glc in 
plasma than the obese population under control conditions (P = 0.076) compared to 
after blackberry exposure (P = 0.11). When results from total anthocyanin glucosides are 
pooled (cyanidin-3-O-glc plus methylated compounds), there was a subtle trend for 
higher circulating amounts of these compounds in the lean compared to the obese 
group under both control (P = 0.10) and blackberry (P = 0.11) conditions. 
Figure 23 shows the absorption, metabolism, and excretion of flavan-3-ols and 
flavonols over 7 h after a bolus dose of blackberries under both control and treatment 
conditions. Results mainly showed a trend for higher plasma AUC of pooled kaempferol 
and its derivatives (parent compounds and metabolites) in the lean compared to the 
obese group after blackberry exposure (P = 0.082), but this trend was less strong for 

















Figure 20. Representative chromatograms of anthocyanins and their metabolites 
identified in plasma and urine in positive mode. Peak identification: (a) peonidin-glucr 1; 














Figure 21. Representative chromatograms of flavan-3-ols, flavonols and their 
metabolites identified in plasma and urine in negative mode. Peak identification: (a) 









Figure 22. Absorption, metabolism, and excretion of anthocyanins after a bolus dose of 
blackberries. An acute pharmacokinetic assessment determined anthocyanin 
appearance in plasma and accumulation in urine over 7 h in both lean (n = 7) and obese 
(n = 11) populations. Data are displayed as average ± SEM. Box plots display 

















Figure 23. Absorption, metabolism, and excretion of flavan-3-ols and flavonols after a 
bolus dose of blackberries. An acute pharmacokinetic assessment determined flavan-3-
ol and flavonol appearance in plasma and accumulation in urine over 7 h in both lean (n 
= 7) and obese (n = 11) populations. Data are displayed as average ± SEM. Box plots 









Figure 24. Absorption, metabolism, and excretion of total flavonoids (all analytes) after a 
bolus dose of blackberries. An acute pharmacokinetic assessment determined flavonoid 
appearance in plasma and accumulation in urine over 7 h in both lean (n = 7) and obese 
(n = 11) populations. Data are displayed as average ± SEM. Box plots display 









5.3.4 Flavonoid accumulation in urine 
Supporting results observed in plasma, there were differences in absorption and 
metabolism of select anthocyanins with BMI as indicated by clearance and accumulation 
of these compounds in urine (see Figures 22, 23 and 24). For individual anthocyanins, 
there was a trend for the lean group to have greater urinary accumulation of cyanidin-3-
O-glc than obese volunteers under both control (P = 0.079) and blackberry treatment (P 
= 0.068) conditions. In addition, there was a trend for greater amounts of urinary 
peonidin-glc 2 in the lean compared to the obese group under both control (P = 0.056) 
and blackberry treatments (P = 0.059). There was significantly greater total anthocyanin 
metabolite urinary accumulation in lean compared to obese volunteers after blackberry 
treatment (P = 0.015) but not under control conditions (P = 0.074). Finally, when results 
for all anthocyanins were pooled, there was significantly greater urinary accumulation in 
lean compared to obese participants with blackberry exposure (P = 0.016) but not under 
control conditions (P = 0.081). 
For kaempferol-7-O-glycoside, there was significantly greater urinary 
accumulation in lean compared to the obese volunteers under both control (P = 0.013) 
and blackberry (P = 0.011) conditions. No differences in epicatechin metabolism was 
observed with blackberry treatment or BMI. Interestingly, when data from all analytes 
(total flavonoids) are pooled, there was significantly greater urinary accumulation in 
lean compared to obese participants under control (P = 0.037) but not blackberry 
conditions (P = 0.17). There were no statistically significant differences when comparing 




Though the experimental paradigm of an acute PK assessment is most commonly 
used to measure the bioavailability of flavonoids and other bioactive compounds, data 
resulting from these acute experiments may not be representative of chronic dietary 
exposures to flavonoids occurring in broader populations. For instance, a clinical study 
with a two week run-in period providing 800 mg EGCG per day resulted in an 
approximately 60% increase in plasma AUC compared to those not exposed to EGCG 
(Chow et al., 2003). An additional clinical trial detected increases in circulating and 
excreted flavan-3-ols after 7-day repeated exposure to tea (Fung et al., 2013), though 
these results were not corrected for accumulation as in the present study. Our results 
showed differences in the absorption and metabolism of select anthocyanins with a 57% 
increase in the average plasma AUC of a methylated cyandin derivative (peonidin-glc 1) 
in lean participants after blackberry treatment, in addition to a trend for increased 
amounts of total methylated cyanidin derivatives (peonidin-glc 1 plus 2) in the plasma of 
this same group. 
In contrast, Jean et al. (2012) study found no difference in cyanidin-3-O-gluoside 
plasma AUC after participants were given 1 g of black bean seed coat extract daily for 
two weeks (Jeon et al., 2012). However, Jeon et al. only measured cyanidin-3-O-
glucoside and therefore these results may not have captured likely shifts in the 
metabolism of this anthocyanin after the period of repeated exposure. In addition, our 
study did not utilize isolated anthocyanins, but rather a whole food, which generally 
results in lower absorption, and potentially reduced metabolism,  compared to isolated 
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flavonoids (Clifford et al., 2013). These differences in experimental design may also 
indicate that adaptation in absorption and metabolism may differ depending on 
whether a flavonoid is provided in a purified/extract form or in the context of a diet 
which may result in interactions between food macro- and micronutrients (Bordenave 
et al., 2014; Guo et al., 2013; Peters et al., 2010), in addition to synergistic properties of 
flavonoid mixtures (Tagashira et al., 2012). Ultimately, it is crucial to consider absorption 
and metabolism of these compounds in the context of a whole food, where there can be 
multiple interactions between food components and flavonoids (Zhang et al., 2004; Zhu 
et al., 2008). 
Our data appear to demonstrate differential adaptation in the metabolism of 
anthocyanins with repeated exposure to blackberry between lean and obese subjects. 
For example, there was significantly greater total anthocyanin metabolite urinary 
accumulation in lean compared to obese volunteers after blackberry treatment, while 
there was no difference under control conditions. In contrast, there was no statistically 
significant difference in urinary accumulation of unmetabolized cyanidin-3-O-glc 
between groups after blackberry treatment or during the control period. Thus, the 
increase in the accumulation of anthocyanin metabolites in lean but not obese 
participants after blackberry exposure may indicate Phase II systems being differentially 
induced with repeated exposure due to BMI. Though there may be differences in urinary 
output, the values presented are volume corrected. The lack of a similar shift in the 
anthocyanin metabolites of the obese group may support the notion of a fundamental 
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difference in the metabolism of these compounds in various disease states such as 
obesity and diabetes (Xiao and Högger, 2014). 
The metabolites detected in this study align with previous reports that observed 
key Phase II metabolites of anthocyanins as the methyl and glucuronide derivatives, 
especially those found in urine (Felgines et al., 2005). In addition, a tracer study that 
provided 13C-labeled cyanidin-3-O-glucoside to humans volunteers reported similar 
Phase II metabolites as identified in the present study, namely the glucuronide and 
methyl glucuronide metabolites (Czank et al., 2013; de Ferrars et al., 2014). Finally, a 
study that provided an acute dose of 200 g of blackberries to humans observed 
glucuronide and methyl glucuronides as the major Phase II metabolites (Felgines et al., 
2005), which corresponds with our analysis.  
In regards to the metabolite profile, it appears that there is greater inter-
individual variability in the metabolite concentrations with repeated exposure to 
blackberry, especially in regards to the anthocyanins (see box plots in Figure 22, 23, 24). 
This variability in metabolites appears to indicate differences in the adaptive response, 
which may reflect genetic polymorphisms in the xenobiotic metabolizing systems that 
result in a system more or less susceptible to induction (Ramos et al., 2014).  
Experiments reported in Chapters 4 and 5 of this dissertation modeled the 
repeated exposure paradigm in humans intestinal Caco-2 cells to determine whether 
adaptation in flavonoid transport and metabolism occurred with repeated exposure. 
Chapter 4 demonstrated that pretreatment with isolated flavan-3-ols increased 
appearance of methylated derivatives, which corresponds to the increases in peonidin 
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levels observed in plasma with repeated exposure. Additionally, there were increases in 
transport of select flavan-3-ols when cell monolayers were pretreated with tea and 
grape seed extracts. In Chapter 5, experiments utilized a composite blackberry extract 
produced from the berries used in this clinical study. Interestingly, pretreatment with 
the extract overall resulted in decreased transport of flavonoids, though we were 
unable to detect metabolites in this model. Analysis of gene expression data of key 
transport and metabolizing systems revealed alterations with repeated blackberry 
exposure, indicating that the gut may potentially be a driver of differences observed in 
absorption and metabolism of flavonoids.  
Though the mechanisms behind these adaptive phenomena are not well 
understood, it is known that the intestinal enterocytes have a high turnover rate and 
the nascent cells repopulating the epithelial lining can be influenced by the extracellular 
matrix (Reya and Clevers, 2005). Thus it is possible that dietary factors including 
flavonoids can influence the differentiating cell’s function leading to altered 
bioavailability. Supporting this notion are in vitro, cell-based data demonstrating that 
Caco-2 cell monolayers undergoing repeated treatment with flavonoid-rich extracts of 
grape products during the differentiation process exhibit altered markers of 
differentiation (Laurent et al., 2004, 2005). Additionally, transport systems such as OAT 
(organic anion transporters) in liver tissue can be altered by long-term treatment of 
anthocyanins (Riha et al., 2015). Thus, there are likely alterations occurring at the 
molecular level over a 3-week period that may relate to the the observed differences in 
the absorption and metabolism of these flavonoids. Although the exact tissue-level 
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alterations are yet unknown, the gut and liver are potential candidates since they are 
major sites of metabolism and transport of these compounds. 
In contrast to previous literature that observed adaptation to extracts rich in 
flavan-3-ols in rodent models (Ferruzzi et al., 2009; Wang et al., 2012), the present study 
did not observe significant differences in plasma AUC or urinary accumulation of 
epicatechin metabolites with repeated exposure to blackberry. Lack of an adaptive 
response may be due to differences food matrix, interactions between flavonoids, or 
phylogenetics. In addition, the differing doses need to be considered as the amount of 
epicatechin in blackberry (approximately 0.6 mg/g) was relatively low compared to that 
of grape seed extracts which can contain up to approximately 60 mg/g epicatechin 
(Villani et al., 2015). Still, because of the relatively small amount of participants in this 
study (n = 18) differences that are not significant should be taken with caution. The 
study appears to be statistical underpowered as a post-hoc power analysis reveals that 
at least 38 participants would be needed to detect significance differences in lean and 
obese cyanidin-3-O-glc appearance in urine.  
Though anthocyanins are considered to have the lowest oral bioavailability of the 
flavonoids when solely considering the parent compound, in fact, they have a much 
higher systemic bioavailability (approximately 20%) when considering both Phase II and 
microbial metabolites of these compounds (Czank et al., 2013). In the present study, we 
focused on the parent compounds and their Phase II metabolites although some studies 
using animal models report that gut microbiota adapts with repeated exposure to 
flavonoids and other phenolics (Wang et al., 2015). These bacterial metabolites should 
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be considered in future studies as the production of these compounds likely changes in 
humans with repeated exposure to flavonoids.  
Strengths of this study include its controlled, randomized, cross-over design. Also, 
possible variation in flavonoid absorption due to of differences in background diet were 
reduced through standardization of the diet in the three weeks leading up to the PK 
assessment. One of the study’s limitations include its relatively short duration since 
broad dietary patterns are generally longer than this period of time. In addition, our 
small sample size may have decreased the ability to detect differences. Though we 
tracked parent flavonoids and their Phase II metabolites, shifts in gut microbial 
populations through diet modifications may result in increased production of low-
molecular weight flavonoid catabolites that are not accounted for in the current analysis.    
   
5.5 Conclusion 
While pharmacokinetic assessments used in determining the bioavailability of 
flavonoids have typically been performed using a paradigm of acute oral doses, the 
current findings suggest that adaptation in absorption and metabolism of select 
flavonoids may occur over three weeks of repeated exposure to blackberry as part of a 
mixed diet. The present study showed that in lean but not obese individuals, plasma 
AUC of methylated derivatives (peonidin-glc) of cyanidin-3-O-glc increased after 
repeated exposure to blackberry. In addition, metabolism of flavonoids appeared to 
differ based on the BMI of the individual, as this study observed increased urinary 
accumulation of anthocyanin metabolites in lean but not obese individuals after 
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undergoing repeated exposure to blackberry. Further research should continue to 
characterize this adaptive effect to isolate specific molecular mechanisms and locations 
(gut, liver, etc) for these phenomena in order to better leverage these findings for the 
purposes of optimizing delivery and dietary recommendations consistent with 
prevention of chronic disease. These data also help inform recommendations for the 
increasingly common issue of obesity in both industrialized and even developing 
countries, since this population may have altered metabolism of flavonoids. Additionally, 
results suggest that further knowledge of adaptation to repeated exposure of flavonoid-
rich foods may better inform our understanding of the true extent of the bioavailability 
of these compounds and dietary/physiological factors that impact these measures. 
Taken together, these data demonstrate that repeated exposure to flavonoid-rich foods 
more consistent with their inclusion in a longer term dietary patterns may lead to a 
different bioavailabilities for individual flavonoids compared to those observed from a 











CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Overall Conclusion  
Though consumption of foods rich in flavonoids including beverages and fruits 
such as tea, grape, and berries have been associated with decreased risk of various 
chronic diseases, application for chronic disease prevention has been argued to be 
limited since their acute oral bioavailability is low (less than 5%). Still, chronic dosing 
paradigms have been reported to increase systemic bioavailability of flavonoids in both 
animal (Ferruzzi et al., 2009; Wang et al., 2012) and human models (Chow et al., 2003). 
Characterization of the absorption and metabolism of flavonoid-rich foods and the 
factors that influence bioavailability are essential in order to correlate epidemiological 
observations to chronic disease preventative endpoints. This dissertation aimed to fill 
the knowledge gap with special focus on adaptive phenomena that influence 
bioavailability of flavonoids such that it can be leveraged for maximizing flavonoid 
bioavailability. More specifically, it aimed to model adaptive phenomena observed in 
vivo by utilizing an in vitro, cell-based model of the small intestinal epithelial cells in 
order to determine alterations occurring at the gut level from repeated exposure to 
flavonoids in addition to characterizing metabolites that result from xenobiotic 
metabolism of flavan-3-ols such as from tea and grape seed. 
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First, the circulating flavan-3-ol metabolite profile of rodents administered grape 
seed was elucidated through a combination of our collaborators supplying us with 
enzymatically-synthesized flavan-3-ols metabolites combined with our use of NMR and 
MS to characterize the structure of these compounds. To summarize, Chapter 2 
concluded that the flavan-3-ols metabolites appearing in rodent plasma could be 
matched with enzymatically synthesized glucuronide and methyl glucuronide flavan-3-ol 
metabolites. By using 1D and 2D NMR spectroscopy, we showed that methylation 
occurs at the 3’ position of both catechin and epicatechin and that major sites of 
glucuronides occur at the 5 and 7 positions. In addition, a two-site laboratory validation 
demonstrated that the analytical method we developed were robust across instruments 
and personnel. Interestingly, we also identified a large difference in the mass 
spectrometry analysis response factor between the parent compound and glucuronide 
metabolites of flavan-3-ols, which may lead to an overestimation of these metabolites in 
biological samples and is not regularly accounted for in these types of analyses.  
Once the chemical structure of the circulating flavan-3-ol metabolites found in 
rodents administered grape seed extract was determined, we turned to the research 
performed in Chapter 3 that highlighted the effect of chronic exposure of the isolated 
flavan-3-ols EGCG and EC in addition to tea and grape seed extracts rich in flavan-3-ols 
on their intestinal transport using the Caco-2 intestinal cell culture model. We 
concluded that repeated low-dose (1-10 µM) exposure to these compounds and 
extracts during the cell differentiation period increased transport of these compounds 
and altered its metabolite profile. Interestingly, treatment with these extracts also 
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appeared to affect the barrier function of the cell model. Limitations of this model is 
that it considers only the gut as an agent of flavonoid bioavailability and metabolism, in 
addition to that metabolites were not detectable when using enriched extracts.  
Given that chronic exposure to isolated flavan-3-ols and enriched extracts were able to 
affect their intestinal transport and metabolism, we turned to probing additional classes 
of flavonoids and phenolic acids by utilizing blackberry extract. We used a similar 
chronic dosing paradigm as described in Chapter 3 to test if low dose exposure resulted 
in differences in transport of the various phenolic compounds. We interestingly 
observed an overall decrease in the transport of the parent compounds with repeated 
exposure, though we were unable to detect the metabolites. Gene expression analysis 
of the xenobiotic metabolizing and transport systems indicated an overall decrease in a 
majority of these systems, which correlated to the decreases in transport of select 
flavonoids and phenolic acids. As in the limitations in the previous chapter, we were not 
able to detect metabolites using this model but the utility of this model is still apparent.  
Taken together, Chapter 3 and 4 suggest that gut adaptation to flavonoids may 
be class specific and dependent on matrix and interactions between flavonoids. For 
instance, tea and grape contain largely monomeric and polymeric flavan-3-ols, while 
berries contain large amounts of anthocyanins, flavonols, and phenolic acids. This 
deserves further investigation as knowledge of differences in adaptation to specific 
classes of flavonoids and food helps determine factors that influence adaptive 
responses in humans.  
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Finally, we performed a clinical study to characterize in vivo adaptation by 
determining the effect of repeated 3-week exposure to blackberry fruit on the 
absorption and metabolism of flavonoids, in addition to determining any effect of BMI 
on these endpoints. Chapter 5 concluded that adaptation in bioavailability and 
metabolism in humans occurs after 3-week daily exposure to flavonoid-rich blackberry. 
The amount of blackberries administered in the study was 300 g or approximately 4 
servings of fruit, which was divided between breakfast and dinner meals. The amount of 
berries given at the PK assessment (300 g) is approximately that recommended by the 
2015 Dietary Guidelines for Americans. Anthocyanins, flavan-3-ol, and flavonol parent 
compounds and metabolites were the major flavonoids detected in circulation and 
found accumulated in urine. Plasma AUC of methylated cyanidin-3-O-glc derivatives 
increased after chronic exposure, possibly indicating induction of metabolizing enzyme 
systems. Interestingly, epicatechin-3’-O-glucr appearance in plasma or its accumulation 
in urine did not appear to be influenced by either blackberry exposure or BMI, which is 
in contrast to previous animal work. This may be due to several factors, including 
differences between humans and rodents, along with dosage and food matrix.  
In conclusion, bioavailability of select flavonoids from blackberries appears to 
change based on previous exposure to these compounds, in addition, the adaptive 
response and absolute bioavailability of these compounds may be influenced by BMI. 
This is of interest because of the large increase in the incidence of obesity in both 
industrialized and developing countries and thus may affect recommendations for these 
compounds. However, for some specific classes of flavonoids, such as flavan-3-ols, 
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bioavailability and metabolism may not be as negatively affected compared to other 
classes. This may be a reflection of differences in specific transport and metabolizing 
systems these compounds undergo. When comparing results from the in vitro data from 
the Caco-2 model to the in vivo data, there are some correlation but also differences. 
Flavan-3-ols from the tea and grape chronic treatment displayed increases in transport, 
and pure compounds generally showed increases in metabolism. In contrast, results 
from blackberry treatment did diverge slightly from this, showing decreases in transport 
of parent compounds. However, this model was limited since we were not able to 
detect metabolites, so any shift in metabolism would not be captured.  
 
6.2 Future Directions  
Our data demonstrated that adaptation can occur in humans and that the gut 
likely plays a vital part in the alterations that occur with repeated exposure. While the 
data is promising, the speculation on the mechanism of whether adaptation in the 
absorption and metabolism of flavonoids in humans are entirely due to the gut needs 
further investigation. In addition, the effect of the obese condition on the mechanisms 
of flavonoid absorption and metabolism needs to be further characterized. It has been 
shown that impaired insulin signaling that can occur with obesity may alter expression 
of drug metabolizing enzymes responsible for glucuronidation and sulfation of flavonoid 
metabolites (Kim and Novak 2007). This change in activity of Phase II metabolizing 
enzymes is likely to alter the generation of conjugated flavonoid metabolites. It will be 
interesting to further explore whether the function of these xenobiotic systems are 
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compromised in obese populations. Future work can incorporate additional aspects of 
human physiology into our reductionist model of the small intestine epithelia to 
generate a more complex model since xenobiotic metabolism involves more than the 
gut, with the liver and kidney also playing integral roles. Finally, changes in the 
absorption and metabolism of these compounds is especially interesting in potential 
biomarkers of intake. If these markers produce robust responses and differences 
between individuals who are habitual versus sporadic consumers, there is more 
potential for candidate markers to be identified and used in large epidemiological 
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Appendix A Weekly Meal Composition for Blackberry Study 
Appendix Table A. 1. Example meal composition for study participants during controlled 
feeding periods.  
 










Appendix Figure A. 1. Macronutrient distribution of an example meal for study 










Appendix B Flavonoid Stabilization Procedure for Urine and Plasma 
Human Plasma acidification protocol for Stabilizing (non-anthocyanin) Flavonoids 
 Freshly prepare 1% ascorbic acid/water (weight:volume) by dissolving 10 g L-
ascorbic acid (catalogue# A92902, Sigma-Aldrich) into 1 L of nanopure water 
 Aliquot 250 μL of ascorbic acid solution into each 2 mL EDTA-cyrovial, keeping 
vials cold on ice 
 Aliquot 1 mL of plasma into vial with the ascorbic acid solution  
 Transfer plasma to -80°C 
Human Plasma acidification protocol for Stabilizing Anthocyanins 
 Prepare a 12.5% (v/v) formic acid (catalogue# 695076 Sigma-Aldrich) solution by 
bringing 125 mL formic acid up to 1 L with nanopure water 
 Aliquot 120 μL of 12.5% formic acid solution into each 2 mL EDTA-cyrovial, 
keeping vials cold on ice 
 Aliquot 1 mL of plasma into vial with the formic solution  
 Transfer plasma to -80°C  
Human Urine acidification protocol for Stabilizing All Flavonoids 
 Prepare a 1% (v/v) formic acid (catalogue# 695076 Sigma-Aldrich) solution by 
bringing 10 mL formic acid up to 1 L with nanopure water 
 Dilute urine at a ratio of 1:5 1% formic acid:urine 
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